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Abbreviations
AA-NHS Acetic acid N-hydroxysuccinimide ester
Acryl Acrylamide
ATS Activated Thiol Sepharose
BCA Bicinchoninic acid
Bisacryl Bisacrylamide
ßNA ß-Naphthylamide
BSA Bovine Serum Albumin
CNS Central Nervous System
Da Daltons
DEAE Diethylaminoethyl
DEPC Diehtylpyrocarbonate
DMSO Dimethylsulphoxide
DTT Dithiothreitol
EDC 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide
EDTA Ethylenediaminetetraacetic acid
EG-NHS Ethylene Glycol-bis(succinic acid N-hydroxysuccinimide ester)
Ex/Em Excitation/Emission
HC1 Hydrochloric acid
H.R. High Resolution
IAA Iodoacetic acid
Kj Inhibitor Dissociation Constant
X Wavelength
LHRH Luteinizing Hormone Releasing Hormone
MCA 7-Amino-4-Methyl-Coumarin
NaCl Sodium Chloride
N.D. Not Determined
NEM N-Ethylmaleimide
NHS N-Hydroxysuccinimide
PAGE Polyacrylamide Gel Electrophoresis
PAP-I Pyroglutamyl Aminopeptidase type-I
The following abbreviations are used throughout this text.
III
PAP-H Pyroglutamyl Aminopeptidase type-II
PDMK pGhi-Diazomethyl ketone
PEG Polyethylene Glycol
pGCK pGlu-chloromethyl ketone
pGlu Pyroglutamic acid
PMSF Phenylmethylsulphonylflouride
pNA p-Nitroanilide
SD Standard Deviation
rpm Revolutions per minute
RSH Thiol Reducing Agent
S2 Supernatant
SDS Sodium Dodecyl Sulphate
SH Sulphydryl
T3 Triiodothyronine
T4 T etraiodothyronine
TEMED N, N, N, N'-Tetramethyl ethylenediamine
TNBS 2,4,6 Trinitrobenzene Sulphonic Acid
TNM Tetranitromethane
TRH Thyrotropin Releasing Hormone
Tris Tris(hydroxymethyl)amino methane
v/v Volume per volume
w/v Weight per volume
Z- N-Benzyloxycarbonyl-
Z-pGCK Z-pGlu Chloromethyl ketone
Z-pGDK Z-pGlu Diazomethyl ketone
IV
Amino Acid Abbreviations
Ala/A Ala
Arg/R Arginine
Asn/N Asparagine
Asp/D Aspartic acid
Cys/C Cysteine
Gln/Q Glutamine
Glu/E Glutamic acid
Gly/G Glycine
His/H Histidine
De/I Isoleucine
Leu/L Leucine 
Lys/K Lysine 
Met/M Methionine 
Phe/F Phenylalanine 
Pro/P Proline 
Ser/S Serine 
Thr/T Threonine 
Trp/T Tryptophan 
Tyr/Y Tyrosine 
Val/V Valine
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Abstract
Cytosolic bovine brain pyroglutamyl aminopeptidase was purified from whole brain by 
chromatography with DEAE sepharose, G100 gel filtration and ATS 4B affinity chromatography. 
An overall recovery of 14.4% and a purifiaction factor of 247 was achieved.
The relative molecular mass of PAP-I, determined by SDS PAGE, was found to be 24,680 Da. The 
partially purified and purified enzyme was found to be relatively unstable under assay conditions. Of 
all the additives tested as stabilisers only BSA was found to stabilise the enzyme, during assay and 
during storage. A minimum concentration of approximately 0.1% w/v BSA was found to achieve 
optimum stabilisation.
PAP-I was confirmed to be a cysteine protease based on its sensitivity to IAA, NEM and 
iodoacetamide. The enzyme was also inhibited by DEPC and EDC, suggesting that His and Glu 
and/or Asp are also involved in events at the active site. These results were confirmed by the 
protective effect of the competitive inhibitor TRH on inactivation of PAP-I by these modifying 
reagents. Cys and His may constitute the nucleophilic and imidazole residues of the active site, while 
Asp or Glu might constitute the third part of the active site. Tyr, Lys, Arg and Ser are not involved 
in the expression of activity.
Initial chemical modification studies demonstrated that EG-NHS modified PAP-I showed almost a 
two fold increase in thermostability over the native enzyme. AA-NHS modified enzyme, did not 
show any increase in thermostability.
X
Introduction
1.1 Pyroglutamic acid
Pyroglutamic acid (pGlu), also known as pyrrolidonc carboxylic acid (PCA, pyr) and 5-oxo-L- 
proline is a cyclical amino acid with unique properties. Although it can be formed non-enzymatically 
(Sanger et al., 1955; Winstead and Wold, 1962), the enzymatic formation of pGlu from glutamic 
acid has been well established (Orlowski and Meister, 1971). This reaction is catalysed by D- 
glutamic acid cyclotransferase. It has been suggested that the role of this enzyme may be to detoxify 
D-glutamic acid, which can be formed by the intestinal flora, or introduced through the diet 
(Orlowski and Meister, 1971).
L-glutamine cyclotransferase, discovered in Papaya latex by Messer (1963), catalyses the conversion 
of glutamine and glutaminyl peptides to pyroglutamic acid and pyroglutamyl peptides respectively. 
This enzyme has not yet been found in animal tissue, however, the conversion of glutamine to 
pyroglutamic acid by a two step enzyme catalysed reaction has been observed. Glutamine can be 
converted to y-glutamyl-glutamine by the enzyme y-glutamyl transpeptidase and subsequently 
converted to pyroglutamic acid by y-L-glutamyl-cyclotransferase (Orlowski et al., 1969). This 
enzyme is widely distributed in animal tissues with the highest levels of activity being found in the 
brain. Orlowski and Meister (1971) suggest that this wide distribution implies significance for this 
enzyme. A mammalian glutaminyl cyclase, capable of converting glutaminyl peptides into peptides 
was identified by Fischer and Spiess (1987).
The enzymatic synthesis of pGlu suggests that this residue may have important biological and 
physiological functions. Consistent with this is the observation that the N-terminus of many proteins 
and bioactive peptides ends in pGlu (see table 1.1) and that the activity of some bioactive peptides is 
usually associated with the presence of an N-terminal pGlu (Abraham and Podell, 1981). Moreover, 
as a free acid, pGlu has been found in the tissues of patients with Hawkinsinuria disease (Borden et 
al., 1992). An increased level of free pGlu has been shown in the plasma of patients with 
Huntington’s disease (Uhlhass and Lange, 1988). This amino acid has been found to prevent 
scopolamine-induced amnesia and electroconvulsive shock in rats (Spignoli et al., 1987) and to 
improve learning and age associated memory loss (Grioli et al., 1990). In addition to the 
aforementioned physiologically relevant properties of pyroglutamic acid, its presence at the N- 
terminus of polypeptides may minimise their degradation, or provide them with a particular function.
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Peptide/Protein Sequence
TRH pGlu-His-Pro-NH2
Neurotensin pGlu-Leu-Try-Glu-Asn-
Bombesin pGlu-Gln-Arg-Leu-Gly-
Eledoisin pGlu-Pro-Ser-Lys-
Anorexogenic pGlu-His-Gly-OH
Fibrinopeptidase:- Human pGlu-Gly-Val-Asp(NH2)-
- Reindeer pGlu-Leu-Ala-Asp-
- Bovine pGlu-Phe-Pro-Thr-Asp-
Gastrin: - Human pGlu-Gly-Pro-Trp-Leu-
- Porcine pGlu-Gly-Pro-T rp-Met-
Vasoactive Polypeptide pGlu-Val-Pro-Trp-
Heavy Chain from Human Pathological IgG pGlu-Val-Thr-
Heavy Chain of Human yG Immunoglobulin pGlu-Val-Gln-Leu-
Heavy Chains of Rabbit Anti-Hapten Antibodies pGlu-Ser-Leu-Glu-Glu-
pGlu-Ser-Val-Glu-Glu-
Heavy Chains of Rabbit IgG pGlu-Ser-Val-Glu-Glu-
pGlu-Ser-Leu-Glu
pGlu-Glu(NH2)
Mouse A, Chains pGlu-Ala-Val-Val-
Human apoLp-Gln-II pGlu-Ala-Lys-Glu-Pro-
Thymic from Porcine Serum pGlu-Ala-Lys-Ser-Gln-
Peptide Inhibiting Epidermal Mitosis pGlu-Glu-Asp-Cys-Lys-OH
Colon Mitosis Inhibitory Peptide pGlu-Glu-His-Gly-OH
Caerulein pGlu-Gln-Asp-Try(S0 3 H)-
Levitide pGlu-Gly-Met-Ilc-Gly-T ry-
Human Monocyte Chemoattractant pGlu-Pro-Asp-Ala-Ile-
Growth Hormone from Tilipia pGlu-Gln-Ile-Thr-Asp -
(Taken from Awade et al. (1994) and subsequently modified.)
Table 1.1 Some Peptides and Proteins with an N-terminalpGlu Residue
1.2 Pyroglutamyl Aminopeptidases
Aminopeptidases (EC 3.4.11.1-14) are N-terminal exopeptidases involved in protein modification 
and in particular, protein and peptide metabolism. They exhibit specificity for the hydrolysis of 
peptide bonds which contain the aminoacyl residue present at the N-terminus of polypeptides. 
Omega peptidases (EC 3.4.19) are exopeptidases capable of removing terminal residues that (a) lack 
a free a-amino or a-carboxyl group (i.e. the pyroglutamyl and aminoacylamide groups), or (b) are 
linked through a sissile bond that involves a carboxyl or amino group which is not attached to an a- 
carbon (McDonald and Barrett, 1986).
Pyroglutamyl aminopeptidases (PAPs) represent one of a class of omega peptidases which 
specifically remove the L-pyroglutamyl residue from the amino terminus of polypeptides by 
hydrolysis (see fig 1.2). Pyroglutamyl aminopeptidase has also been referred to as pyrrolidonyl 
peptidase, pyrrolidonecarboxylyl peptidase, pyrrolidonecarboxylate peptidase, pyroglutamyl 
arylamidase, pyroglutamate aminopeptidase, pyroglutamyl peptidase, L-pyroglutamyl peptide 
hydrolase, PYRase and 5-oxoprolyl-peptidase (Awadc et al., 1994). To date, two classes of 
pyroglutamyl aminopeptidase have been characterised. The first includes bacterial pyroglutamyl 
aminopeptidase and animal type-I pyroglutamyl aminopeptidase (PAP-I), a soluble enzyme with 
biochemical characteristics similar to the bacterial PAPs. The second class includes mammalian 
typc-II pyroglutamyl aminopeptidase (PAP-II), a membrane bound enzyme and scrum PAP, also 
known as Thyroliberinase (Bauer et al., 1981). Enzymes from these two classes present distinct 
differences in their cellular and subcellular localisation, molecular weights and enzymatic properties.
R
R
PAP + HnN ---- C H ------ C —NH C -----  NH C -
h2 o NH
O O
Pyroglutamyl-peptide Pyroglutamic acid n-1 peptide
Figure 1.2 Hydrolysis o f  pGlu from the N-terminus o f L-pGlu-proteins or 
L-pGlu-peptides by PAP.
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1.2.1 Class-I: Animal PAP-I and Bacterial PAPs
PAP activity was first discovered in a strain of Pseudomonas fluorescens by Doolittle and 
Armentrout (1968) who found that a crude extract could hydrolyse the pyroglutamyl dipeptide L- 
pGlu-L-Ala to yield free pGlu and alanine. PAP has since been observed in the tissues of mammals, 
birds, fish, plants and bacteria.
1.2.1.1 Biochem ical and Biophysical Characteristics o f Class-I PAPs
With the exception of Klebsiella coacae enzyme, which is associated with the particulate fraction 
(Kwiatkowska et al., 1974), all of the bacterial PAPs studied to date have been shown to be soluble 
proteins located in the cell cytosol (Tsuru et al., 1978; Awade et al., 1992b). The hydrophobic 
character of four bacterial PAPs indicates that the charge of these enzymes is uniformly distributed 
along the polypeptide. This is consistent with the observation that the enzymes are soluble proteins 
(Kyte and Doolittle, 1982). Mammalian PAP-1 (EC 3.4.19.3), like its bacterial counterpart, is also a 
soluble cytosolic enzyme (Mudge and Fellows, 1973; Browne and O’Cuinn, 1983; Lauffart et al., 
1988; Cummins and O’Connor, 1996). The enzyme has been found to be present in all mammalian 
tissues tested, with the exception of blood (Szewczk and Kwiatkowska, 1970). The regional 
distribution of the enzyme in the supernatant fractions of rat brain reveals less than two fold 
variation in regions from lowest to highest concentrations (Friedman and Wilk, 1986).
The mammalian PAP-I is a monomeric enzyme with a molecular weight of 22,000 to 25,000 Da 
(Mudge and Fellows, 1973; Browne and O'Cuinn, 1983, Mantle et al., 1991; Cummins and 
O'Connor, 1996). The molecular weight of the bacterial enzyme, under non-denaturing conditions, 
has been shown to vary from 50,000 to 91,000 Da. Tsuru et al. (1978; 1984) have proposed that the 
B. amyloliquefaciens PAP, with a native molecular weight of 72,000 Da and a subunit molecular 
weight of 24,000 Da, probably functions as a trimer. More recently however, Yoshimoto et al. 
(1993) have cloned the gene for the B. amyloliquefaciens enzyme and, following its overexpression 
in E. coli, have shown that the recombinant enzyme appears to exist as a dimer. This suggests that 
the recombinant form of the enzyme differs from the natural form, possibly due to different post- 
translational processing patterns in the host cell. Other studies indicate that the recombinant PAPs 
from B. subtilis (Gonzales and Awade, 1992; Awade et al., 1992b) and S. pyrogens (Awade et al., 
1992a) are probably tetramers, whilst the recombinant PAP from P. fluorescens (Gonzales and 
Robert-Baudouy, 1994) probably functions a dimer.
PAP-I and bacterial PAPs are members of the cysteine proteinase family. The cysteine residue at the 
active site of the enzyme is very labile and thus a thiol-reducing agent such as DTT or 2-
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mercaptoethanol is required for enzyme activity. The enzymes are very sensitive to sulphydryl- 
blocking reagents such as N-ethylmaleimide, 2-iodoacetamide, iodoacetate and p- 
hydroxymercuribenzoate and also to trace amounts of heavy metals such as Hg2+, Zn2 , and Cu2+ 
(Doolittle and Armentrout, 1968; Tsuru et al., 1978; Bauer and Kleinhauf, 1980; Browne and 
O'Cuinn, 1983; Ciunmins and O'Connor, 1996).
The overexpressed Bacillus amyloliquefaciens enzyme has been crystallised and therefore 
knowledge of PAP structure is imminent (Yoshimoto et al., 1993). The bacterial PAP genes 
examined so far do not show any significant similarity to other known nucleotide sequences, nor do 
the deduced amino acid sequences compare favourably with protein sequences from other 
prokaryotic and eukaryotic sources. This lack of homology with other proteins, including other 
proteases, suggests that bacterial PAPs belong to a new and unique class of peptidases. All of the 
cloned bacterial PAPs contain a uniquely conserved cysteine residue, suggesting that this residue is 
directly involved in the catalytic site of these thiol dependent enzymes. This has been confirmed by 
alteration of the cysteine residue, which results in total loss of enzyme activity (Yoshimoto et al., 
1993). A histidine residue is also conserved, indicating that this residue may also be essential for 
enzyme activity or substrate binding (Gonzales and Robert-Baudouy, 1994).
Both the animal PAP-I and the bacterial PAPs are unstable and heat sensitive enzymes, being rapidly 
inactivated at temperatures above 50°C. Stabilisation of the enzyme has been achieved using the 
reversible inhibitor 2-pyrrolidone (Armentrout and Doolittle, 1969; Szewczuk and Kwiatkowska, 
1970; Mudge and Fellows, 1973) or by the addition of BSA to the partially purified or purified 
enzyme (Cummins and O'Connor, 1996). Enzyme stabilisation is discussed in further detail in 
section 1.3. Optimal enzyme activity is expressed at pH 8.5 for purified mammalian PAP-I (Lauffart 
et al., 1988; Mantle et al., 1991; Cummins and O'Connor, 1996) and at pH 7.0 to 9.0 for bacterial 
PAP (Doolittle and Armentrout, 1968; Kwiatkowska et al., 1974; Awade et al., 1992a). 
Interestingly, a thermostable PAP from Pyrococcus juriosus has been reported recently (Izu et al., 
1998). This enzyme retains its activity at 75-95°C.
A distinctive biochemical feature of PAP-I is its broad pyroglutamyl-substrate specificity. This 
enzyme is capable of liberating the N-terminal pGlu residue from a range of biologically active 
peptides including TRH, acid TRH, LHRH, neurotensin, bombesin and anorexigenic (Browne and 
O'Cuinn, 1983; Cummins and O'Connor, 1996). Synthetic substrates such as pGlu-MCA, pGlu- 
pNA, pGlu-pNA, and isotopic TRH are also readily hydrolysed by PAP-I, as are synthetic 
dipeptides such as pGlu-Ala and pGlu-Val (Browne and O'Cuinn, 1983; Bauer and Kleinhoff, 1980;
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Albert and Szewczuk, 1972). pGlu-Pro bonds are not normally hydrolysed by either bacterial or 
mammalian PAP-I (Dootittle, 1972; Mudge and Fellows, 1973; Browne and O'Cuinn, 1983; 
Cummins and O'Connor, 1996). However, the enzyme from the particulate fraction of Klebsiella 
coacae was found to be capable of hydrolysing the pGlu-Pro bond (Kwiatkowska et al., 1974). 
Initial PAP assays were based on the cleavage of L-pyroglutamyl dipeptides such as L-pGlu-L-Ala 
and monitoring the amino acid release by the ninhydrin method (Doolittle and Armentrout, 1968). 
The development of the colourimetric and fluorimetric substrates L-pGlu-PNA (Szewczuk and 
Kwiatowska, 1970;), L-pGlu-pNA and L-pGlu-MCA (Fujiwara and Tsuru, 1978) resulted in PAP 
assays with greatly increased sensitivity.
Despite its broad substrate specificity, PAP-I is highly specific for N-terminal pGlu residues. A 
study by Capecchi and Loudon (1985) reports that minor alterations to the pGlu moiety of a given 
substrate has very deleterious effects on the ability of PAP-I to cleave this amino terminal group. 
More recently, Bundgaard and Moss (1989) have exploited this pGlu specificity as a means of 
developing potentially useful “prodrugs” which are resistant to PAP-I attack. These researchers 
demonstrated that altering the N-H group on the pGlu ring, results in a pGlu moiety that is 
completely resistant to cleavage by PAP-I (Moss and Bundgaard, 1989; 1992; Bundgaard and Moss,
1989).
PAP-I levels in mammals are developmentally regulated. One of the more recent studies on this 
measured developmental changes in PAP activities in rat brain cortex and cerebellum (de Gandarias 
et al., 1998). This study demonstrated that PAP-I activity is high in the perinatal period and 
decreases two or three fold subsequently, at a later stage in the cerebellum than in the brain cortex, 
reaching adult levels at the end of the first post natal month. The decrease in the activity of PAP-I 
coincides with increasing concentrations of brain TRH after the second postnatal week. It is 
suggested that PAP-I could play a part in the normal development of rat CNS.
1.2.1.2 Inhibitors o f Class-I PAPs
Potent and specific (both reversible and irreversible) inhibitors of PAP-I have been described. Active 
site directed inhibitors were first synthesised by Fujiwara et al. (1981a, 1981b, 1982), for the B. 
amyloliquefaciens enzyme. These were pGlu-chloromethyl ketone (pGCK), Z-pGlu chloromethyl 
ketone (Z-pGCK) and Z-pGlu-diazomethyl ketone (Z-pGDK). The chloromethyl ketone derivatives 
were found to be highly specific, potent and irreversible inhibitors of this PAP. A three fold molar 
excess of inhibitor was sufficient to inactivate the enzyme by 95% after only one minute incubation. 
This inhibitor was found to be very unstable; therefore, the Z-pGCK derivative was prepared.
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Although this inhibitor inactivated the enzyme at a ten-fold slower rate, it was, nonetheless, quite 
potent.
Aldehydes interact with cysteine proteases forming hemiacetal adducts. The aldehyde derivative of 
pyrogluamate, 5-oxoprolinal, is a potent and specific inhibitor of PAP-I in vitro with a Ki of 20- 
26nM. 5-oxoprolinal is also active but of low potency in vivo when administered to mice, possibly 
due to its rapid metabolism (Friedman et ah, 1985).
pGlu-diazomethyl ketone (PDMK) is an irreversible PAP-1 inhibitor. It is very potent in vivo as well 
as in vitro. One hour following intraperitonal administration of O.lmg/kg to mice, the brain enzyme 
was totally inhibited, and after 24 hours, the enzyme was still 50% inhibited. Since it is an 
irreversible inhibitor, restoration of enzyme activity requires the synthesis of new enzyme (Wilk et 
ah, 1985).
2-pyrrolidone is a pyroglutamyl substrate analogue which acts as a reversible, non-competitive 
inhibitor of PAP-I. As mentioned earlier, several studies have reported on the use of 2-pyrrolidone to 
stabilise PAP-I, either during purification or storage.
1.2.1.3 Physiological Role and current Uses o f Class-I PAPs
As previously mentioned, PAP-I has been shown to act on many different substrates possessing an 
N-terminal pGlu, including TRH. Despite earlier interest in the role of PAP-I in TRH metabolism, it 
appears that this enzyme is not involved in the control of TRH levels in vivo (Mendez et ah, 1990; 
Salers et ah, 1991). This has been demonstrated by the exposure of hypothalamic cells to the PAP-I 
inhibitor, PDMK, which did not change TRH content or recovery of released TRH (Mendez et ah,
1990). The role of PAP-I still remains unclear. It has been proposed that it may contribute to the 
final stages of intracellular catabolism of peptides to free amino acids which are then released to the 
cellular pool (Mantle et ah, 1990; 1992). Thus the enzyme may, at least in part, be involved in the 
regulation of the cellular pool of free pGlu (Awade et ah, 1994). As described in section 1.1, free 
pGlu is known to have pharmacological properties, thus a specific pathway may exist to generate 
this molecule. The source of free pGlu that is associated with the aforementioned diseases remains 
unknown, but the involvement of PAP-I remains a possibility.
In some recent studies, researchers have found an increase in soluble PAP activity in certain 
physiological disorders. Soluble PAP was found to be increased the neurohypophysis and adrenal 
glands of hypertensive rats (Prieto et ah, 1998). Shaw et al. (1996) found that cytosolic PAP
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activity was increased in patients with amylotrophic lateral sclerosis. They have suggested that an 
underlying abnormality of intracellular protein metabolism, in which PAP plays a role, may be 
responsible for the pathogenesis of the disease.
As with the mammalian PAP-I the role of the bacterial PAP remains unclear. This enzyme may be 
involved in the utilisation of peptides as a source of nutrients as suggested in the case of 
Pseudomonas flourescens, which was shown by Doolittle and Armentrout (1968) to be capable of 
growing with free pGlu as the sole source of carbon and nitrogen. Such a role for the enzyme is 
weakened by the observation that it is not commonly found in bacteria, and even within the same 
species some strains possess PAP activity while others lack the enzyme (Szewczuk and Mulczyk,
1969). Awade et al. (1994) proposed that the high accumulation of peptides with an N-terminal 
pGlu may abnormally acidify the cell cytoplasm, possibly indicating a role in detoxification.
The absence of an a-amino group in pGlu-peptides and proteins was, for many years, a major 
impediment in the characterisation of these materials, since amino terminal analysis, including 
stepwise degradation methods (Edman, 1950), could not be carried out. Consequently the initial 
impetus behind the discovery of PAP (Doolittle and Armentrout, 1968) was to isolate an enzyme 
activity that would render terminal amino groups accessible in pGlu-terminating peptides. In this 
regard, PAP (typically commercial calf liver PAP-I or bacterial PAP) has been extremely successful 
(Podell and Abraham, 1978). Indeed, despite the availability of enzymatic and chemical methods to 
open pGlu rings (Miyatake et al., 1993; Van der Werf et al., 1975), and physical methods such as 
mass spectrometry, which are available to overcome sequencing difficulties due to the N-terminal 
pGlu block (Khandke et al., 1989), PAP still remains the de-blocking method of choice for many 
sequencers (Mozdzanowski et al., 1998; Lu et al., 1991)
Since PAP activity is present in some bacterial strains but is absent in others, specific PAP-I assays 
have been used in bacterial diagnostic techniques. For example, PAP activity has been exploited in 
diagnostic tests for the identification of streptococcal species (Wellstood, 1987; Panosian and 
Edberg, 1989; Dealler et al., 1989) and more recently in the identification of Salmonella species 
(Inoue et al., 1996).
1.2.2 Class-II: Animal PAP-II and Serum PAP
In the late 1970s a pyroglutamyl aminopeptidase which cleaved the pGlu-His bond of TRH was 
partially purified from rat (Taylor and Dixon, 1978) and porcine (Bauer and Nowak, 1979) serum. 
Unlike the previously characterised cytosolic PAP-I activity, this enzyme was not inhibited by
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sulphydryl-blocking reagents such as 2-iodoacetamide and N-ethylmaleimide but could be inhibited 
by metal chelators such as EDTA and 1,10 phenanthroline. The molecular weight of the enzyme was 
found to be approximately 260,000 Da, an order of magnitude greater than the soluble PAP-I. Bauer 
et al. (1981) demonstrated that the selectivity of this enzyme was directed towards TRH or closely 
related peptides. Other pGlu substrates such as pGlu-pNA, LHRH and neurotensin were not 
cleaved. As a consequence of this narrow substrate specificity, the name “thyroliberinase” was 
subsequently proposed (Bauer et al., 1981).
While several authors had reported that PAP activity was associated, at least in part, with the 
particulate fraction of brain (Schock, 1977; Hayes et al., 1979; Griffiths et al., 1979; Greaney et al., 
1980), Browne et al. (1981) were the first to demonstrate the existence of two distinct pyroglutamyl 
aminopeptidases in guinea pig brain. They found the particulate enzyme, in marked contrast to the 
soluble enzyme, was inhibited by DTT and EDTA. These observations were later confirmed by the 
findings of O'Connor and O'Cuinn (1984) who localised this particulate activity to the synaptosomal 
membrane preparations of guinea pig brain from which it could be solubilised by papain treatment. 
PAP-II has a molecular weight of 230,000 Da, consisting of two identical subunits of approximately 
116,000 Da cach (Bauer, 1994). Like serum “thyroliberinase”, PAP-II has a substrate specificity 
restricted to TRH or closely related peptides.
This unprecedented degree of specificity for a particular peptide configuration, combined with the 
knowledge that (1) the active site of PAP-II appears to be extracellular (Charli et al., 1988), (2) it is 
primarily located within neuronal elements of the CNS, (3) it has a differential distribution within the 
CNS and (4) the inhibition of PAP-II specifically increases recovery of TRH released from rat brain 
tissue (Charli el al., 1989), would serve to indicate that the particulate PAP activity is responsible 
for specifically inactivating ncuronally released TRH within the extracellular vicinity of target cells. 
Several studies reporting on the influence of thyroid hormones on PAP-II activity support this 
observation. Suen and Wilk (1989) and Bauer (1987, 1988) have clearly demonstrated the 
significantly increased TRH-degrading action of PAP-II in the anterior pituitary following acute 
treatment with triiodothyronine (T3). Such tissue specific regulation of adcnohypophyseal PAP-II by 
thyroid hormones suggests that it may serve an integrative function in modulating the response of 
adenohypophyseal target cells to TRH by terminating the biological activity of the tripeptide at this 
location, the increased TRH-degrading activity subsequently contributing to the negative feedback 
effect of thyroid hormones on the hypothalamic production of TRH. Wilk (1986) has subsequently 
proposed that the membrane bound PAP-II be considered the first characterised neuropeptide- 
specific peptidase.
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1.3 Enzyme Stabilisation
The term stability refers to an enzyme's resistance to adverse influences such as heat or other 
dénaturants, that is, to the persistence of its molecular integrity or biological function in the face of 
extremes of temperature or other deleterious influences. A perfectly folded, fully functional 
monomeric enzyme can lose its biological activity in vitro by unfolding of its tertiary structure to a 
disordered polypeptide, in which key residues are no longer aligned closely enough for continued 
participation in functional or structure-stabilising interactions. Such unfolding is termed 
dénaturation. It is usually cooperative and may be reversible if the denaturing influence is removed. 
An enzyme is also subject to chemical changes, which lead to an irreversible loss of activity or 
inactivation, particularly following unfolding ” (O’Fagain, 1997).
*
“ The use of enzymes is unfortunately quite restricted for a number of reasons. Notable among these is 
the loss of enzyme function with time. Recently, understanding of both inactivation processes and of 
stabilising interactions has increased, which has lead to improvements in enzyme stability. This has 
been achieved through protein engineering. This, however, can be quite a complex task and simpler 
stabilisation alternatives are available. These include the use of additives (usually solutes) and 
chemical modification. One of the main aims of these techniques is to reduce the lability of enzymes 
since enzymes with increased stability are often required for different applications, such as organic 
synthesis or for use in biosensors ” (O’Fagain, 1997).
1.3.1 Use o f Stabilising Additives
It has long been known that inclusion of low molecular weight substances can greatly stabilise the 
critical enzymes biological activity. A variety of compounds can increase the stability of enzymes in 
solution.
1.3.1.1 Types o f Stabilising M olecules
The range of stabilising additives is very wide.
1.3.1.1.1 U se of Salts
Certain salts can significantly stabilise enzymes in solution. This effect varies with the constituent 
ions in the Hofmeister series, which relates to ionic effects on protein solubility. This series ranks 
both cations and anions in order of their stabilising effects. The most stabilising ions are on the left, 
whereas those on the right are actually destabilising.
10
(CH3)4N+ > NH4+ > K+,Na+ > Mg2' > Ca2+ > Ba 2+ 
S042- > Cl > Br > NO3' > CIO^ > SCN'
The stabilising ions force enzyme molecules to adopt a tightly packed, compact structure by salting 
out hydrophobic residues. This helps prevent the unfolding, which is the initial event in any enzyme 
deterioration process. Certain ionic compounds such as glycine can also exert stabilising effects. 
These act by shielding charges and can stabilise enzymes at low concentrations; typical 
concentrations range from 20 to 400mM.
1.3.1.1.2 Use o f Osmolytes
Osmolytes are a diverse group of substances comprising such compounds as polyols, sugars, 
polysaccharides, neutral polymers (such as PEG) and amino acids and their derivatives. In general, 
they affect water's bulk solution properties by forming many hydrogen bonds and aid formation of a 
'solvent shell' around the enzyme molecule that is distinct from the bulk aqueous phase. They do not 
interact with the protein directly. Many of these compounds are found in vivo to control the osmotic 
pressure of eucaryotic and bacterial cells.
Sugars and polyols are used at high final concentrations: typical figures range from 10-40% w/v (O 
Fagain, 1997). Sugars are thought to be the best stabilisers. They stabilise the lattice structure of 
water, thus increasing surface tension and viscosity. They stabilise hydration shells and protect 
against aggregation by increasing the molecular density of the solution (Schein, 1990).
Glycerol is a very widely used low molecular weight polyol. Its advantages include its ease of 
removal by dialysis and its non-interference with ion exchange chromatography. Its stabilisation 
effect appears to be due to the formation of tight hydrogen bonds between the polyol and the water 
resulting in a reduction of water activity and an increase in solvent structure. The protein is less able 
to unfold against a more structured polyol-water solvent than it is against water alone (O Fagain et 
al., 1988). However, its main drawback is that it is a excellent bacterial substrate. It has been 
suggested that the five-carbon sugar, xylitol, can be an effective alternative glycerol (O Fagain, 
1997). Xylitol can be recycled from buffers and it is not a convenient food source for bacteria.
Polymers such as PEG generally increase solvent viscosity and thereby help prevent aggregation. It 
has also been suggested that PEG brings about a change in the enzyme's solvent interactions 
resulting in a tightening of chain folding and progressive exclusion of water molecules from the 
relatively hydrophobic core of the enzyme, to which water had been previously able to gain access
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(Mozhaev and Martinek, 1984). This results in a more compact hydrophobic core and an enzyme 
with improved stability (Ó Fágáin etal., 1988). Typical final concentrations of PEG range from 1 to 
15% w/v. Amino acids with no net charge, notably glycine and proline, can act as stabilisers if used 
in the range 20-500mM. They usually stabilise enzymes via weak electrostatic interactions.
1.3.1.1.3 Other Common Additives
Addition of specific substrates or competitive (reversible) inhibitors to purified enzymes can often 
exert great stabilising effects. Occupation of the enzyme's binding site(s) by these substances leads to 
minor, but significant conformational changes in the polypeptide backbone. The enzyme adopts a 
more tightly folded conformation, reducing any tendency to unfold and (sometimes) rendering it less 
prone to proteolytic degradation. Occlusion of the enzyme's active site(s) by a bound reversible 
inhibitor will protect those amino acid side chains that are critical for function. The reversible 
inhibitor, 2-pyrrolidone, has been used to stabilise PAP-I (see section 1.2.1.1).
The thiol group of cysteine is prone to destructive oxidative reactions. One can prevent or minimise 
these by using reducing agents such as 2-mercaptoethanol or dithiothrcitol. Much of the oxidation of 
thiol groups is mediated by divalent metal ions, which can activate molecular oxygen. Complexation 
of free metal ions (where they are not themselves essential for activity) can prevent destructive 
oxidation of thiol groups. Chelating agents such as EDTA may be used to complex metal ions. 
Indeed both DTT and EDTA have been routinely used in the assay mixture for the determination of 
PAP-1 activity and during PAP-I purification (Browne and O'Cuinn, 1983a; Cummins and 
O'Connor, 1996).
Very dilute protein solutions are highly prone to inactivation and therefore should be concentrated as 
rapidly as possible. Where this is not possible, one can prevent inactivation by addition of an 
exogenous protein such as bovine serum albumin (BSA), typically to a final concentration of 
lmg/mL. There are numerous reasons for the undoubted benefits of BSA addition (Scopes, 1994). 
BSA may act to prevent target protein adsorption to the container surfaces, it may prevent 
dissociation of subunits or it may even act in a chaperonin-like manner to prevent unfolding of the 
protein of interest. It is often included in reaction mixtures to stabilise dilute enzyme solutions. BSA 
has been used by researchers to stabilise PAP-I either during assay or storage (Browne and O'Cuinn, 
1983a; Cummins and O'Connor, 1996). As well as a great number of polar and charged groups on 
the surface of enzymes, there are some nonpolar (hydrophobic) residues whose contact with water is 
thermodynamically unfavourable (Mozhaev and Martinek, 1984) and this can actually destabilise 
enzymes (Mozhaev et al., 1988). BSA is a very hydrophobic molecule (Bigelow, 1967); therefore,
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hydrophobic interactions with exposed hydrophobic groups on the enzyme of interest may lead to 
increased stability. Moshaev and Martinek (1984) noted that these interactions make an important, if 
not decisive, contribution to the maintenance of the native structure of enzymes. When the enzyme- 
BSA complex forms, the contact area of the nonpolar fragments with water decreases, the free 
energy of the system diminishes and hence the stabilisation takes place (Mozhaev and Martinek, 
1984).
1.3.2 Use o f Chemical M odifications
Chemical modification provides an alternative to the inclusion of the additives mentioned above. 
Because purified PAP-I is an unstable enzyme (section 1.2.1.1), the main aim of chemical 
modification would be to increase its stability. . Each of the 20 amino acids occurring in enzymes 
has a free R-group or side chain. Many of these have reactive functional groups such as the thiol 
group of cysteine or the amino group or lysine residues. At least 9 amino acid side chains (Cys, Lys, 
Asp and Glu, Arg, His, Trp, Tyr, Met) can react with specific reagents under mild conditions to 
yield chemically-modified protein derivatives, often with altered properties. Two distinct chemical 
modification strategies can benefit protein stability. These are (i) crosslinking, either intra- or 
intermolecular and (ii) surfacc group modification.
1.3.2.1 Use o f Cross-Linking Reagents
Cross-linking of enzymes with bi(poly)-functional agents is widely used for protein stabilisation. The 
employment of external 'braces' prevents both the unfolding of the tertiary structure and the 
dissociation of oligomeric proteins into subunits (Mozhaev and Martinek, 1984). Inactivation is 
always a danger, since some of the amino acid side chains will be essential for function. For example 
reagents targetting cysteine groups should not be used with PAP-I since this residue has been found 
to be essential for activity (section 1.2.1.1). But careful choice of modifying agent(s) and conditions 
can often minimise activity losses.
Bifunctional crosslinking reagents are chemicals with two reactive functions, specific for a particular 
amino acid R-group, separated by an unreactive middle portion. They are either homobifunctional, in 
which both reactive groups are the same, or heterobifunctional, in which both the functional groups 
are different. Homobifunctional reagents include imidoesters and bismaleimides that are amino- and 
thiol-group specific respectively. Heterobifunctional reagents include derivatives of N- 
hydroxysuccinimide that are specific for both amino and thiol groups. Means and Feeney (1990) and 
Ji (1983) give a comprehensive list o f homo- and hetero-bifiinctional crosslinking reagents. Thiol and 
amino groups are frequently targeted because they are reactive and occur frequently in protein
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primary structures. Other groups or side chains that can be targeted include carboxyl groups on 
aspartyl and glutamyl residues, guanidino groups of arginine residues and imidazole groups of 
histidine residues. Molecular rigidification is achieved by crosslinking, i.e., by the reaction of both 
functional groups of the bifunctional reagent with the enzyme backbone. Thus the reagents allow 
free, soluble enzymes to be stabilised against denaturation.
The success or failure in increasing enzyme stability by treatment with bifiinctional reagents largely 
depends on the length of the bifunctional molecule, and hence on the distance between the molecular 
centres to be crosslinked (Torchilin et al., 1978). Thus, a crosslinking reagent may form molecular 
bridges in one type of enzyme molecule and not in another. When successful crosslinking occurs, it 
implies that the targeted enzyme has molecular distances that suited the crosslinking reagent 
employed. Certain workers have quite successfully stabilised enzymes by arranging intra- or inter- 
molecular cross-links of defined lengths using these reagents (O Fagain et al., 1988).
I.3.2.1.1 Crosslinking with N-Hydroxysuccinimide Esters
N-Hydroxysuccinimide (NHS) esters are among the most popular of the modifying reagents, because 
of their mild chemical reaction conditions coupled to their commercial availability and ease of 
synthesis. They can be either homo- or hetero-bifunctional (Ji, 1983). Reaction of NHS-esters occurs 
most efficiently at pH 7-8 in most buffers that do not contain free amino groups. Reaction is rapid, 
with most accessible protein amino groups attacked within 10 to 20 minutes at temperatures ranging 
from 4-25°C.
Unfortunately NHS-esters are poorly soluble in aqueous buffer and need to be dissolved in a minimal 
volume of an organic solvent such as DMSO, prior to enzyme addition. This may cause problems if 
high concentrations of modifier are required as high solvent concentrations may lead to some 
inactivation. Therefore, at the very least, appropriate controls must be included to account for this 
possibility.
The NHS reaction scheme is shown in figure 1.3.3. The principle product of reaction with an amine 
is an amide; thus the positive charge of the original amino group is lost. The reaction involves the 
nucleophilic attack of an amine on the acid carboxyl of an NHS-ester to form an amide, releasing the 
NHS.
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N-Hydroxysuccinimide Ester Amine Amide N-Hydroxysuccinimide
Figure 1.3.3 N-Hydroxysuccinimide Ester Reaction Scheme
1.3.2.2 Surface Group M odification
Crosslinking is not a prerequisite for stabilisation. Dramatic increases in stabilisation can result 
merely from the alteration of surface groups. As with crosslinking inactivation is a possibility but 
this can be avoided through careful choice of modifier. But a number of distinct advantages also 
exist. Relatively little structural information is required concerning the target protein, as is the case 
with PAP-I. The experiments are often quick and simple to carry out and protocols may be readily 
implemented.
Ô Fâgâin (1997) has described some of the chemical modification reagents that have been used in the 
past with varying degrees of success with numerous enzymes. Mozhaev et al., 1988 has achieved 
considerable stabilisation via hydrophilisation of the protein surface, which reduccs unfavourable 
surface hydrophobic contacts with water. The modified enzyme, in which the non-polar surface area 
was reduced, was shown to be more stable against irreversible thermoinactivation than the native 
enzyme. Through chemical modification it has also been possible to change the pH optima of 
enzymes, the relative reactivity towards substrates and the pattern of substrate and product 
inhibition.
Many of the reagents used in alteration of surface groups have also been of great value in the 
investigating the nature of the active site residues. They can distinguish, for example, serine from 
cysteine proteases by the use of appropriate reagents. It can identify those amino acids that 
participate in catalysis and those that are important in substrate binding. Few, if any, chemical 
modifiers are absolutely specific for a given type of functional group. The outcome of the 
modification can be influenced, to some degree, by every type of experimental variable (Cohen,
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1970). Table 1.3.2 lists some reactive amino acid R-groups and some of the compounds used for 
their modification.
Amino acid Side Chain Reagents Reaction Ref
Cysteine Thiol N-ethylmaleimide Alkylation 1.
Lysine Amino 2,4,6 Trinitrobenzene
Sulphonic acid Addition 1.
Arginine Guanidino Phenylglyoxal - 2,
Histidine Imidazole Diethylpyrocarbonate Addition 3.
Aspartic acid Carboxyl Carbodiimides Amidation 4.
Glutamic acid Carboxyl Carbodiimides Amidation 4.
Tryosine Phenol T etranitromethane Nitration 5.
Table 1.3.2 Amino Acid Side Chains and Reagents for their modification
1. Ô Fâgâin, 1997; 2. Takahashi, 1977; 3. Dickenson and Dickenson, 1975; 4. Carraway and 
Koshland, 1972; 5. Riordan and Vallee, 1972b.
There are also a variety of other methods by which stabilisation can be achieved. These are based on 
the strengthening of hydrophobic interactions by non-polar reagents and the introduction of new 
polar or charged groups that give additional ionic or hydrogen bonds to the enzyme molecule (O 
Fagain and O'Kennedy, 1991).
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Materials and Methods
2.1 M aterials
Sigma Chemical Company (Poole, Dorset, England):
AA-NHS
Acetaldehyde
Ammonium persulphate
Bovine Serum Albumin
Diethylpyrocarbonate
2,2'-dithiopyridine
EDTA
EG-NHS
EDC
Glycine
2-Iodoacetamide 
lodoacetic acid 
Laurel sulphate 
2-Mercaptoethanol 
MCA
N-acetylimidazole 
N-ethylmaleimidc 
N,N'-Methylene-Bisacrylamide
Phenylglyoxal
Potassium phosphate (dibasic) 
Potassium phosphate (monobasic) 
Proline
Pyridoxal phosphate 
Rose bengal 
Sephadex G-25 
Silver stain high MW kit 
Silver stain kit 
Sodium chloride 
Sucrose 
TEMED
T etranitromethane
2,4,6 trinitrobenzene sulphonic acid
Xylitol
Bachem Feinchemikaiein AG (Bubendorf, Switzerland): 
pGlu-MCA Thyroliberin
BDH Chemicals Ltd. (Poole, Dorset, England):
Acrylamidc Glacial acetic acid
Bromophenol blue Glycerol
Citric acid Hydrochloric acid
Dimethylsulphoxide Polyethylene Glycol 6000
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Ammonium sulphate Sodium hydroxide
Potassium chloride
Aldrich Chemical Company (Poole, Dorset, England):
2-Pyrrol idone
Pharmacia Fine Chemical Company (Uppsala, Sweden):
Activated Thiol Sepharose 4B DEAE-Sepharose Fast Flow
Phenyl Sepharose CL-4B Sephadex G-I00
Melford Laboratories (Chelsworth, Ipswich, Suffock, England)
Tris buffer Dithiothreitol
Bio-Rad Laboratories (Hercules, California, USA):
Bio-Rad protein assay dye reagent concentrate 
Kepak Meats (Clonee, Co.Meath, Ireland):
Bovine whole brain
Pierce Chemical Company (Illinois, USA):
BCA reagent
Merck Chemical Company (Frankfurt, Germany):
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2.2.1 Cytosolic Pyroglutamyl Am inopeptidase in Crude Samples
Cytosolic pyroglutamyl aminopeptidase (PAP-I) activity was determined according to a modification 
of the method of Cummins and O’Connor (1996) (see Fig 2.2.1). 100|iL of sample was incubated 
for 1 hour at 37°C with 400(xl of O.lmM pGlu-MCA in 50mM potassium phosphate buffer pH 7.4 
containing lOmM DTT, lOmM EDTA and 0.75% v/v DMSO. The reaction was terminated by the 
addition of lmL of 1.5M acetic acid. All assays were performed in triplicate and suitable negative 
controls were prepared by adding acetic acid to the enzyme prior to the substrate. Liberated MCA 
was determined using a Perkin-Elmer LS50 Fluorescence Spectrophotometer with excitation and 
emission wavelengths of 370nm and 440nm respectively. Excitation slit widths were maintained at 
lOnm while emission slit widths were adjusted as appropriate for the level of flourescence produced. 
Samples containing particulate material were centrifuged at 13000 rpm for 10 minutes, using a 
Heraeus Sepatech Biofiige A prior to flourescence reading.
2.2.2 Cytosolic Pyroglutamyl Am inopeptidase in Purified Samples
Purified preparations of the enzyme (i.e. pooled post gel filtration and affinity chromatography 
samples) were assayed as outlined in section 2.2.1 with the following exception. 80[iL of sample was 
incubated for 1 hour at 37°C with 20|xL of lOmg/mL protease free BSA and 400fxL of O.lmM 
pGlu-MCA in 50mM potassium phosphate buffer, pH7.4 containing lOmM DTT, lOmM EDTA 
and 0.75% v/v DMSO. Liberated MCA was determined as outlined in section 2.2.1.
2.2.3 M icroplate Assay
In addition to the assays outlined in sections 2.2.1 and 2.2.2, a non-quantitative microplate assay 
was devised to facilitate the detection of cytosolic PAP in the large number of fractions generated by 
column chromatography. Two assays were employed in order to detect enzyme activity. In the first 
method (used for post ion-exchange fractions) 100(a,L of substrate (O.lmM pGlu-MCA + lOmM 
DTT + lOmM EDTA as in section 2.2.1) was added to 50(j,L of sample. After incubation of this 
mixture at 37°C for 30 minutes, the reaction was terminated by the addition of lOOpL of 1.5M 
acetic acid. The second method (used for post gel filtration and post affinity chromatography 
fractions) involved adding 100(iL of substrate to a mixture of 40pL of sample and 10fxL of 
lOmg/mL protease free BSA. This mixture was incubated at 37°C for 30 minutes after which the 
reaction was terminated by the addition of 100|xL of 1.5M acetic acid. Suitable negative controls for 
both methods were included on each plate by adding acid to the sample prior to the substrate.
2.2 Determ ination o f Enzym e Activities
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Liberated MCA was detected in the same manner as outlined in section 2.2.1 using a Perkin-Elmer 
LS50 Fluorescence Spectrophotometer fitted with a microplate reader.
Assay protocol:
1. (a) 10()(jL  of sample + 400(iL of O.lmM pGlu-MCA or
(b) 80|xL of sample + 20fiL of BSA + 400fiL of 0. ImM pGlu-MCA
2. React at 37°C for 60 minutes
3. Stop reaction with lmL of 1.5M acetic acid
4. Read fluorescence at Ex: 370nm and Em: 440nm
Assay schematic:
pGlu-MCA
pGlu MCA “Liberated”
Fluorescence
(Ex X: 370nm, Em X: 440nm)
Fig 2.2.1 Assay o f  cytosolic PAP activity using pGlu-MCA
2.3 7-Amino-4-Methyl-Coumarin Standard Curves
In order to quantify the activity of cytosolic PAP using "quenched" fluorometric substrates, 7- 
Amino-4-Methyl-Coumarin (MCA) standard curves were constructed. A 200f.iM MCA stock in 2% 
v/v DMSO was prepared in 50mM potassium phosphate buffer, pH 7.4, at 37°C. This stock 
solution was stored in the dark at 4°C. Lower concentrations of MCA were achieved using 50mM 
potassium phosphate buffer, pH 7.4 as diluent. Standard curves were constructed by substituting the 
appropriate MCA standard for substrate under the assay conditions described in sections 2.2.1 and 
2.2.2. Ranges of 0-1.ó^-M, 0-8|a.M and 0-80p,M MCA were prepared. Fluorometric intensity was 
measured using a Perkin-Elmer LS50 Fluorescence Spectrophotometer with excitation and emission
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wavelengths of 370nm and 440nm respectively. Excitation slit widths were maintained at lOnm 
while emission slit widths were adjusted to produce fluorimetric intensities appropriate for the range 
being analysed.
A unit of enzyme activity was defined as that which liberates one nanomole of MCA per minute at 
37°C. Conversion of fluorometric intensities to units of enzyme activity was achieved using the 
following formula:
Units per mL = Fluorometric Intensity x 0.0667
Slope
The 'slope' is obtained from an appropriate MCA standard curve. The factor 0.0667 considers the 
method of preparation of the standard curve, the conversion of |iM to nanomoles, the conversion of 
hours to minutes and the conversion from "per 80|j.L" or "per lOOpL" to "per mL" of sample.
2.4 Protein Determination
2.4.1 Absorbance at 280nm
The absorbance of proteins based on the A™ of tryptophan and tyrosine residues at 280nm was used 
as a non-quantitative method of determining protein concentrations in post column chromatography 
fractions. A Shimadzu UV 160A Spectrophotometer was used to determine this absorbance.
2.4.2 Standard Bicinchoninic Acid Protein Assay
The Bicinchoninic Acid (BCA) protein assay, based on the method of Smith et al., (1985), was used 
for the determination of protein concentration in crude homogenate, supernatant (S2) and pooled post 
anion exchange samples. These samples were dialysed for 20 hours against 50mM potassium 
phosphate buffer, pH 7.4 to remove interfering substances such at Tris/HCl buffer, DTT and 
EDTA. Before dialysis, the homogenate was rehomogenised to remove particulate material using a 
hand operated homogeniser and subsequently diluted in 50mM potassium phosphate buffer, pH 7.4. 
Samples with a protein concentration outside the limits of the BCA assay (0.02-1.8mg/mL) were 
diluted as appropriate in 50mM potassium phosphate buffer, pH 7.4. 200|xL BCA working reagent 
was added to 10pL of dialysed and/or diluted sample in triplicate in a 96 well microplate and 
incubated for 30 minutes at 37°C, after which the absorbance at 560nm was measured using a
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TiterTek Multiscan PLUS spectrophotometric plate reader. A 0-1.8mg/mL BSA standard curve was 
prepared and assayed in parallel with samples each time it was performed.
2.4.2.1 Enhanced Bicinchoninic Acid Protein Assay
This assay was used to monitor the protein in post affinity chromatography fractions. The assay was 
performed as described in section 2.4.2 with the following exceptions, fractions were dialysed 
extensively against distilled water and an incubation temperature of 60°C was used.
2.4.3 Biorad Protein Assay
The Biorad protein assay, based on the method of Bradford (1976), was used to determine protein 
concentration in pooled post gel filtration and affinity chromatography samples. These samples were 
dialysed for 20 hours against distilled water in order to remove interfering substances. 0.8mL of 
dialysed sample was incubated with 0.2mL of Biorad working reagent in triplicate at room 
temperature for 5 minutes after which, the absorbance at 595nm was read on a Shimadzu UV 160A 
spectrophotometer. A 0-24|xg/mL BSA standard curve was prepared in parallel with the assay each 
time it was performed.
2.5 Purification of PAP-I from Bovine Brain Cytosol
Cytosolic pyroglutamyl aminopeptidase was purified according to a modification of the method of 
Cummins and O'Connor (1996). All steps were performed at 4°C unless otherwise stated.
2.5.1 Tissue Preparation and Centrifugation
25g of bovine brain was homogenised in lOOmL of 50mM Tris/HCl buffer at pH 8.0 containing 
2mM DTT and 2mM EDTA with the aid of a Sorvall Omni Mixer. Tissue was disrupted by three 7 
second pulses at a speed setting of five with a 20 second pause between pulses. 80mL of the crude 
homogenate was then centrifuged for 45 minutes at 15,000 rpm (27,200g) using a Beckman J2-MC 
refrigerated centrifuge fitted with a JA-20 rotor. The supernatant (Si) was retained while the pellet 
was resuspended in 40mL distilled water (osmotic shock) using four up and down strokes of a 40mL 
Glas-Col hand held pestle and tube homogeniser. The resuspended pellet was centrifuged as before. 
The resulting supernatant was combined with Si to form S2 while the new pellet was discarded.
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2.5.2 DEAE Sepharose Fast Flow Anion-Exchange Chromatography
An 18mL DEAE Sepharose column (2.5cm x 3.7cm) was equilibrated with lOOmL of 50mM 
Tris/HCl buffer at pH 8.0 containing 2mM DTT and 2mM EDTA. 40mL of supernatant (S2) was 
applied to the column, after which the column was washed with 120mL of equilibration buffer. The 
column was then eluted with a 60mL linear 0-0.75M NaCl gradient in equilibration buffer. 5mL 
fractions were collected during sample application and wash stages and 3mL fractions were collected 
during elution. A flow rate of 2mL/min was maintained throughout this procedure. All fractions were 
assayed for cytosolic PAP activity and protein as outlined in sections 2.2.3 and 2.4.1 respectively. 
Fractions containing the highest PAP-I activity were pooled.
2.5.3 Sephadex G100 Gel Filtration
The post DEAE Sepharose PAP-I was concentrated six-fold via reverse osmosis using polyethylene 
glycol. Glycerol was added to the concentrated sample to a final concentration of 10% v/v. A 230mL 
Sephadex G100 gel filtration column (2.5cm x 47cm) was equilibrated with 350mL of 50mM 
Tris/HCl buffer at pH 8.0 containing 2mM DTT, 2mM EDTA and lOOmM KC1. lmL of 
concentrated sample was loaded under the buffer head, after which the column was washed with 
220mL of equilibration buffer. After 50mL had passed through the column, 5mL fractions were 
collected. A flow rate of 0.5mL/min was maintained throughout this procedure. All fractions were 
assayed for cytosolic PAP activity and protein as outlined in sections 2.2.3 and 2.4.1 respectively. 
Fractions containing the highest PAP-I activity were pooled.
2.5.4 A ctivated Thiol Sepharose 4B Affinity Chromatography
A 13mL Activated Thiol Sepharose 4B column (1.5cm x 7.2cm) was equilibrated with lOOmL of 
50mM Tris/HCl at pH 8.0 containing 2mM EDTA and 0.3M NaCl. 2QmL of pooled post gel 
filtration PAP-I was dialysed for 3 hours against 1L of 50mM Tris/HCl buffer at pH 8.0 containing 
2mM EDTA (this buffer was changed after 1.5 hours) before being applied to the column at a 
flowrate of 0.25mL/min. The column was washed with 20mL of equilibration buffer at 0.25mL/min, 
followed by a further 20mL at a flowrate of 0.5mL/min. Elution was achieved isocratically with 
50mL of lOmM DTT in equilibration buffer. A flow rate of 0.5mL/min was maintained during the 
equilibration and elution stages. 5mL fractions were collected during sample application and wash 
stages and 3mL fractions collected thereafter. All fractions were assayed for cytosolic PAP activity 
and protein as outlined in sections 2.2.3 and 2.4.2.1 respectively. Fractions containing the highest 
PAP-I activity were pooled. Protease free BSA, to a final concentration of 0.2% w/v, was added to 
this purified enzyme, which was subsequently stored at -80°C. Unless otherwise indicated, this was 
the form of the purified enzyme used for characterisation and stabilisation studies.
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2.6 Polyacrylamide Gel Electrophoresis
SDS polyacrylamide gel electrophoresis (SDS PAGE) was carried out on the various fractions 
generated throughout the purification procedure, from crude cytosol (S2) to purified PAP-I (post 
affinity chromatography), to assess the efficiency of the purification procedure, according to the 
method of Laemmli (1970). Deionised water was used throughout this procedure.
2.6.1 Sample Preparation
Samples to be electrophoresed were dialysed extensively for 24 hours against 1L 62.5mM Tris/HCl, 
pH 6.8, at room temperature with buffer changes after 3, 6, and 18 hours. Dialysed samples were 
diluted appropriately in 62.5mM Tris/HCl at pH 6.8 and subsequently mixed with an equal volume 
of sample solubilisation buffer which consisted of 20% v/v glycerol, 8% w/v SDS, 10% v/v 2- 
mercaptocthanol and 0.01% w/v bromophenol blue in 62.5mM Tris/HCl, pH 6.8. Table 2.6.1 lists 
the silver stain molecular weight standards used. All samples were incubated for 1.5 minutes in a 
boiling water bath and placed on ice prior to loading onto the gel.
Molecular Weight Standard Source Molecular Weight (Daltons)
ß-Galactosidase E. Coli 116,000
Phosphorylasc B Rabbit muscle 97,000
Albumin Bovine serum 66,000
Fumarasc Porcine heart 48,500
Carbonic anhydrase Bovine erythrocytes 29,000
Table 2.6.1. Molecular Weight Markers used for SDS PAGE
2.6.2 Gel Preparation and Electrophoresis
The following stock solutions were prepared:
Resolving gel buffer 
Stacking gel buffer 
Acryl/Bisacryl stock 
Ammonium persulphate 
SDS
Electrode buffer
3M Tris/HCl at pH 8.8
0.5M Tris/HCl at pH 6.8
30% w/v acrylamide, 0.8% w/v bisacrylamide
1.5% w/v, freshly prepared
10% w/v
0.192M Glycine, 0.1%w/v SDS and 0.025M 
Tris/HCl at pH 8 .3
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A 160mm x 160mm x 1mm, 10% resolving gel overlayed with a 3.75% stacking gel was cast in an 
Atto vertical electrophoresis Midi system. The volumes of the various solutions used to prepare the 
gels are shown in table 2.6.2. 20(xL of the appropriately prepared samples were loaded onto the gel 
which was electrophoresed in the elecrode buffer. Electrophoresis proceeded for approximately 4 
hours at 25mA per gel.
2.6.3 Silver Staining
A Sigma AG25 silver stain kit was employed to perform the silver staining of SDS PAGE gels 
according to the method of Heukeshoven and Demick (1985). Table 2.6.3 outlines the staining 
procedure. This procedure was followed for the staining of gels with the exception of the reducing 
step which was deemed unnecessary. Digital images of gels were obtained using a UVP ImageStore 
7500. This incorporated a UVP White/UV Transilluminator/Camera unit driven by ImageStore 7500 
software. Images acquired were either stored digitally on disk, or printed using a Sony Videographics 
Printer UP-860 CE.
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Solution Volume Required for 
10% Resolving gel
Volume Required for 
3.75% Stacking Gel
Acryl/Bisacryl stock lOmL 2.5mL
Resolving gel buffer 3.75mL -
Stacking gel buffer - 5mL
SDS 0.3mL 0.2mL
Deionised water 14.45mL 11.3mL
Ammonium persulphate 1.5mL lmL
TEMED 15|o,L 15^L
Table 2.6.2. SDS Gel Electrophoresis Gel Preparation
Step Reagent Volume Duration
1. Fixing 30% v/v EtOH,
10% v/v Glacial Acetic Acid
300mL x 3 20 min x 3
2. Rinsing Deionised Water 300mL x 3 10 min x 3
3. Silver Staining Silver Nitrate 300mL 30 min
4. Rinsing Deionised Water 300mL 10-20 sec.
5. Developing Sodium Carbonate, Formaldehyde 150mL x 2 5-8 min x3
6. Development Stop 1% v/v Acetic Acid 300mL 5 min
7. Rinsing Deionised Water 300mL x 3 10 min x 3
8. Reducing Potassium Ferricyanide, Sodium 
Thiosulphate, Sodium Carbonate
300mL 10-30 sec.
9. Rinsing Tap Water Running Water 1 min
10. Rinsing Deionised Water 300mL x 3 10min x 3
Table 2.6.3. Recommended Silver Staining Procedure for SDS PAGE Gels
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2.7 Development of the pGlu-MCA Based Assay
2.7.1 Linearity o f the pGlu-M CA Assay w ith Respect to Time
The linearity of the pGlu-MCA based assay with respect to time was investigated. This study was 
performed on the various fractions generated throughout the purification procedure, from the crude 
cytosol (S2) to purified PAP-I (post affinity chromatography). These samples were assayed as 
outlined in section 2.2.1 except that the assays were terminated with 1.5M acetic acid after 10, 20, 
30, 40, 50 and 60 minutes.
2.7.2 Effect o f BSA  on a Purified Preparation o f Cytosolic PAP during Assay
The effect of BSA on a purified preparation (post affinity chromatography) of cytosolic PAP during 
assay was investigated. The purified sample was added to an equal volume of protease-free BSA to 
give a final concentration of 0 to 3 mg/mL in the enzyme sample. Cytosolic PAP activity was 
determined as outlined in section 2.2.1.
2.7.3 Linearity with Respect to Time in the Presence o f BSA
The linearity of the pGlu-MCA based assay with respect to time in the presence of 2 mg/mL BSA 
was investigated. This study was performed on the post gel filtration and post affinity 
chromatography samples. These samples were assayed as outlined in section 2.2.2 except that the 
assays were terminated with 1.5M acetic acid after 10, 20, 30, 40, 50, and 60 minutes.
2.8 Active Site Studies
The effect of a range of protein modifying reagents on purified PAP-I activity was investigated in 
order to identify the amino acids at the active site of PAP-I that are necessary for the expression of 
activity.
2.8.1 Effect o f M odifying Agents on PAP-I Activity
Stock solutions of a range of protein modifying reagents were prepared as outlined in table 2.8.1. 
Lower concentrations of each were achieved by dilution with 50mM potassium phosphate buffer or 
50mM Tris/HCl, both at the appropriate pH’s. The pH of the stock solutions were adjusted to a 
suitable pH using 50mM monobasic or dibasic potassium phosphate buffer as appropriate or by the 
addition of 1M HC1 when Tris buffer was used.
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Aliquots of purified PAP-I containing 0.2% w/v BSA were dialysed against the appropriate buffer 
used in reagent preparation as outlined in table 2.8.1. For the sulphydryl-blocking reagents, the 
dialysis buffer contained 20nM DTT, 20pM EDTA and 0.1M NaCl and proceeded for 3 hours. For 
the remaining reagents, the dialysis buffer contained 2mM DTT, 2mM EDTA and 0.1M NaCl and 
proceeded for 15 hours.
320(iL of the dialysed enzyme was incubated for 15 minutes at 37°C with 80pL of modifying 
reagent in an appropriate buffer, as indicated in table 2.8.1, and 80pL of the same buffer at the same 
pH. Appropriate controls were set up by substitution of 80(iL of the corresponding buffer for the 
modifying reagent. Some of the modifiers were removed by Sephadex G25 gel filtration as outlined 
in section 2.8.2. Samples (either post incubation or post G25 gel filtration) were assayed for PAP-I 
activity as outlined in section 2.2.1. It should be noted that the samples modified by the sulphydryl- 
blocking reagents were assayed with substrate containing 20(iM DTT and 20^M EDTA. When the 
emyme was incubated with 2,4,6 trinitrobenzene sulphonic acid, pyridoxal phosphate or 
acetaldehyde, parallel incubations were set up with each of these modifying reagents in sodium 
borohydride such that the final concentration of sodium borohydride was 2mM. The effect of each of 
the modifiers not removed by gel filtration on fluorescence was determined as outlined in section 2.3.
2 8
Modifier Concentration
(mM)
Preparation
T etranitromethane 6 50mM Tris/HCl, pH 8.0 a
2,4,6 trinitrobenzene
sulphonic acid 6 50mM Tris/HCl, pH 8.0
Phenylglyoxal 6 5OmM Tris/HCl, pH 8.0
Pyridoxal phosphate 60 50mM Tris/HCl, pH 8.2 b
Acetaldehyde 60 50mM Tris/HCl, pH 8.0
1 -Ethyl-3 -(3 -Dimethylamino-
propyl)carbodiimide 120 50mM potassium phosphate buffer, pH 5.0
120 5OmM potassium phosphate buffer, pH 5.5
60 50mM potassium phosphate buffer, pH 6.0
60 5OmM potassium phosphate buffer, pH 7.0
60 5OmM Tris/HCl, pH 8.0
Diethylpyrocarbonate 60 50mM potassium phosphate buffer,pH 6.0 c
Sulnhvdrvl-blocking reaeents
Rose bengal 60 5OmM Tris/HCl, pH 7.7
Iodoacetamide 60 5OmM Tris/HCl, pH 8.0
Iodoaeetic acid 60 50mM Tris/HCl, pH 8.0
N-Ethylmaleimide 60 50mM Tris/HCl, pH 8.0 b
N-Acetylimidazole 300 50mm Tris/HCl, pH 8.0
Table 2.8.1 Preparation o f Protein Modifying Reagents
a 60mM stock prepared in 100% v/v ethanol 
b dissolution was aided by heating in a boiling water bath 
c 600mM stock freshly prepared in 100% v/v ethanol
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2.8.2 M odifier Rem oval Using Sephadex G25 Gel Filtration
Modifiers were removed from the sample by the method of Helmerhorst and Stokes (1980). 
Sephadex G25 was swollen by constant agitation for 3 hours. lOmL columns (1.5cm x 5.7cm) were 
packed and equilibrated with the dialysis buffer indicated in section 2.8.1. The columns were allowed 
to run dry by centrifugation at 1600rpm for 3 minutes using a Heraeus Sepatech Megafuge 1.0. 
450|^L of post incubation sample was applied to the top of the column while 450|xL of the control 
sample was applied to another column. The columns were centrifuged at 1600rpm for 2 minutes. 
The eluant from each column was collected. The resin was unpacked, swelled and washed before use 
again.
2.8.3 Protection o f the Active Site by the Addition of the Com petitive Inhibitor 
pGlu-H is-Pro-NH2 (TRH).
80pL of 3.75mM TRH in the appropriate buffer was added to 320pL of dialysed enzyme. 80^iL of 
modifying reagent in suitable buffer was then added and the mixture was incubated for 15 minutes at 
37°C. Controls were set up by replacement of 80(_iL of modifying reagent with 80pL of appropriate 
buffer. The treated samples were assayed for PAP-I activity as described in section 2.8.1.
2.8.4 Time Course Inhibition Studies
This study was carried out in order to determine the rapidity with which certain modifiers act on the 
enzyme. This was carried out as outlined in sections 2.8.1 and 2.8.3 except that the enzyme was 
incubated at 37°C with the modifier in the presence and absence of TRH for 0, 2, 5, 10 and 15 
minutes. Controls were set up by substitution of the 80(j,L of modifier or TRH with 80fiL of either 
50mM potassium phosphate or 50mM Tris/HCl buffers at the appropriate pH. Samples were 
subsequently assayed for residual activity.
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2.9 Stability studies
In an attempt to find an alternative stabilising compound to BSA, numerous other potential 
stabilising compounds were tested in order to assess their effectiveness as stabilising compounds 
during assay and during storage. The reasoning behind this was to attempt to further stabilise the 
en2yme using some simple chemical modifying reagents. If  the enzyme was stored in protein, the 
modifying reagents could well react with the high concentration of protein before it could react with 
the enzyme. Therefore an altemative(s) to BSA was sought.
2.9.1 Effect o f Potential Stabilisers on PAP-I Activity
Stocks of various potential stabilisers were prepared as outlined in table 2.9.1. Two parallel assays 
were set up, in order to test two concentrations of each stabiliser. One consisted of adding 125 of 
post ATS pool (with no BSA added) to 125(xL of stabiliser stock and 250pL of 50mM Tris/HCl pH 
8.0. The other consisted of adding 125fiL of post ATS affinity pool (with no BSA added) to 250|iL 
of stabiliser stock and 125p,L of 50mM Tris/HCl pH 8.0. Appropriate controls were set up by 
substitution of the stabiliser stock with the appropriate buffer. lOOfxL aliquots of each of these were 
assayed as outlined in section 2.2.1. The effect of each of the reagents on fluorescence was 
determined as outlined in section 2.3.
Potential Stabiliser Concentration Preparation
BSA 2 mg/mL 50mM Potassium Phosphate pH 7.4
Glycerol 20 %v/v 50mM Tris/HCl pH 8.0
Xylitol 20 %w/v 50mM Tris/HCl pH 8.0
Sucrose 20 %w/v 50mM Tris/HCl pH 8.0
PEG 15 %w/v 50mM Tris/HCl pH 8.0
Glycine 500mM 50mM Tris/HCl pH 8.0
Citrate 500mM NaOH pH 7.0
Proline 500mM 50mM Tris/HCl pH 8.0
Table 2.9.1. Preparation o f potential stabilising reagents
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2.9.2 Stability o f PAP-I During Assay
The linearity of the pGlu-MCA based assay with respect to time was investigated in the presence of 
any of the above reagents that showed potential as stabilisers. This was carried out as outlined in 
section 2.7.3 with the exception that the BSA was replaced with the appropriate concentration of 
PEG. The assay was also carried out in the presence of both BSA and PEG. Suitable controls were 
included by replacing both BSA and PEG with an appropriate buffer.
2.9.3 Stability o f PA P-I During Storage
The stability of purified PAP-I stored at -80°C in the presence of various compounds was 
investigated. The enzyme was stored in 2mg/mL BSA, lmg/mL BSA, 15% v/v glycerol and finally 
with no additions. Aliquots of enzyme stored in the presence of these compounds were removed at 
intervals and assayed for residual PAP-I activity. Samples containing BSA were assayed as outlined 
in section 2.2.1 while samples containing no BSA were assayed as outlined in section 2.2.2.
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2.10 Initial Stabilisation of PAP-I via Chemical Modification
2.10.1 M odification with EG-NHS and AA-NHS
10mg/mL Ethylene Glycol-bis (succinic acid N-hydroxylsuccinimide ester) (EG-NHS) and Acetic 
Acid N-hydroxysuccinimide ester (AA-NHS) stock in 25% v/v DMSO were prepared in lOmM 
potassium phosphate buffer, pH 7.6. Purified PAP-I containing 1 mg/mL BSA was dialysed against 
lOmM potassium phosphate buffer, pH 7.6, containing 2mM DTT, 2mM EDTA and 0.1M KC1. 
Dialysed enzyme was added to the modifier stock such that the enzyme was exposed to 1 mg/mL, 
2mg/mL, 3mg/ml or 4mg/mL of modifier. Suitable controls of unmodified enzyme were included by 
substitution of the modifier with lOmM potassium phosphate buffer, pH 7.6, containing the 
appropriate concentration of DMSO. The modifier was left to react with PAP-I at room temperature 
for 20 minutes. The reaction was terminated by removal of the modifier on a Sephadex G25 column 
pre-equilibrated with lOmM potassium phosphate buffer, pH 7.6, containing 2mM DTT, 2mM 
EDTA and 0.1M KC1, as outlined in section 2.8.2.
2.10.2 Therm ostability o f Native and M odified Enzyme
Native and modified enzyme was preheated to 37°C for 3 minutes followed by heating at 55°C for 10 
minutes. The native and modified enzymes were removed and placed on ice, before assaying for 
residual activity as outlined in section 2.2.1
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Results
3.1 Preparation of MCA Standard Curves
As outlined in section 2.2.1 the specific fluorimetric substrate pGIu-MCA, was used to assay for 
cytosolic PAP activity. The enzymatic release of MCA was monitored fluorimetrically at excitation 
and emission wavelengths of 370 and 440nm respectively. MCA release alone could then be 
quantitated by using a standard curve prepared with the latter compound under corresponding assay 
conditions and read at the corresponding slit widths. Plots of fluorimetric intensity versus MCA 
concentration are presented in figures 3.1.1, 3.1.2, 3.1.3 and 3.1.4. The inner filter effcct observed 
when crude homogenate or S2 were used as the enzyme sample, is demonstrated in figures 3.1.1 and
3.1.2 respectively. It should be noted that the MCA concentration expressed on the x-axis of these 
figures represents the concentration present in the 400 .^L of standard used to construct the curves.
3.2 Protein Standard Curves
Protein standard curves were prepared using BSA as outlined in section 2.4. Plots of absorbance at 
560nm and 595nm versus BSA concentration arc presented. Figure 3.2.1 shows the standard curve 
for the BCA assay, while figure 3.2.2 shows the standard curve obtained for the Biorad assay.
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Figure 3.1.1 MCA Standard curves. Plots of fluorimetrie intensity versus MCA concentration. 
100|iL of buffer (•—•) or lOO^L of crude homogenate (o—o) was combined with 400p,L of a 
standard concentration of MCA and lmL of 1.5M acetic acid before being analysed fluorimetrically 
as outlined in section 2.3. The emission slit width was set at 2.5nm. Error bars represent the SD of 
triplicate readings.
M CA Concentration (nM)
Figure 3.1.2 MCA Standard Curves. Plots of fluorimetrie intensity versus MCA concentration. 
100(xL of buffer (•— •) or lOOpL of S2 (o— o) was combined with 400(xL of a standard 
concentration of MCA and lmL of 1.5M acetic acid before being analysed fluorimetrically as 
outlined in section 2.3. The emission slit width was set at 2.5nm. Error bars represent the SD of 
triplicate readings.
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Figure 3.1.3 MCA Standard Curves. Plot of fluorimetrie intensity versus MCA concentration. 
IOO^ iL of buffer was combined with 400fiL of a standard concentration of MCA and lmL of 1.5M 
acetic acid before being analysed fluorimetrically as outlined in section 2.3. The emission slit width 
was set at 5nm. Error bars represent the SD of triplicate readings.
M CA Concentration ((iM)
Figure 3.1.4 MCA Standard Curve. Plot of fluorimetrie intensity versus MCA concentration. 
100|xL of buffer was combined with 400pL of a standard concentration of MCA and lmL of 1.5M 
acetic acid before being analysed fluorimetrically as outlined in section 2.3. The emission slit width 
was set at lOnm. Error bars represent the SD of triplicate readings.
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Figure 3.2.1 BSA  Standard Curve. Plot of absorbance at 560nm versus BSA  concentration 
obtained using the standard BCA  assay as outlined in section 2.4.2. Error bars represent the SD of 
triplicate readings.
BSA Concentration (jig/ml)
Figure 3.2.2 BSA  Standard Curve. Plot of absorbance at 595nm versus BSA  concentration 
obtained using the Biorad assay as outlined in section 2.4.3. Error bars represent die SD of triplicate 
readings.
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3.3 Purification of PAP-I from the Cytosolic Fraction of Bovine Brain
3.3.1 Tissue Preparation and Centrifugation
80mL of crude homogenate was centrifuged and from this a combined supernatant volume (S2) of 
91mL was obtained. This represented an active recovery of 89.2% of the initial PAP-I activity.
3.3.2 Partial Purification of Cytosolic PAP by Anion-Exchange Chromatography
The ion exchange column was equilibrated as outlined in section 2.5.2. Under these conditions, 
cytosolic PAP bound to the column whilst unbound contaminants were washed through the column 
with approximately 6 column volumes of equilibration buffer. Following the application of the linear 
NaCl gradient, bound PAP-I activity eluted from the column, emerging between fractions 41 and 47 
to give a final volume of 19.9mL when pooled. The active recovery of applied PAP-I activity was 
87.2%. The elution profile of this column is illustrated in Fig 3.3.1.
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Figure 3.3.1 Elution Profile of PAP-I Activity from DEAE Sepharose Fast Flow Anion 
Exchange Chromatography. 40mL of supernatant was applied to an 18mL DEAE Sepharose
column as outlined in section 2.5.2. The column was eluted with a linear NaCl gradient(--------).
Fractions were analysed for PAP-I activity (•—•) as outlined in section 2.2.3 and for protein
( ........ )as outlined in section 2.4.1. Fractions 41-47 were combined to form the post DEAE
Sepharose pool (19.9mL).
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3.3.3 Further Purification of Cytosolic PAP by Gel Filtration Chromatography
Following concentration by reverse osmosis and the addition of glycerol to a final concentration of 
10% v/v, the post ion exchange pool was applied to a Sephadex G100 column as outlined in section
2.5.3. Fractions 21-29 were combined to form the post Sephadex G100 pool (43.5mL). 54.6% of 
PAP-I activity was recovered from this step. The elution profile can be seen in Fig 3.3.2.
3.3.4 Affinity Chromatography of Cytosolic PAP on Activated Thiol Sepharose 4B
20mL of dialysed post gel filtration PAP-I was applied to an Activated Thiol Sepharose 4B column 
as outlined in section 2.5.4. Under these conditions, PAP-I bound to the column whilst unbound 
contaminants were washed through with equilibration buffer. The bound PAP-I was subsequently 
eluted by the inclusion of lOmM DTT in the equilibration buffer, emerging between fractions 19-24 
to give a final volume of 17mL when pooled. The active recovery of applied PAP-I activity was 
33.9%.
The release of 2-thiopyridone from the column was also monitored by absorbance spectrophotometry 
at 343nm. Two distinct peaks of 2-thiopyridone were observed within the elution profile. The first 
peak emerged after sample application, and results from the binding of thiol enzymes to the column 
functional groups. A second peak emerged immediately after elution commenced. The elution profile 
obtained can be seen in Fig 3.3.4
Table 3.3.1 summarises the overall purification scheme
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Figure 3.3.2 Elution Profile of PAP-I Activity from Sephadex G100 Gel Filtration 
Chromatography. Following concentration by reverse osmosis and the addition of glycerol to a final 
concentration of 10% v/v, lm L of concentrated post DEAE Sepharose pool was applied to a 230mL 
Sephadex G100 column as outlined in section 2.5.3. Fractions were assayed for PAP-I activity
(•— •) as outlined in section 2.2.3 and for protein ( ............ ) as outlined in section 2.4.1. Fractions
21-29 were combined to form the post Sephadex G100 pool (43.5mL).
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Figure 3 .3 .4  Elution Profile of PAP-I Activity from ATS 4 B  Affinity Chromatography. 20mL of 
dialysed post gel filtration pool was applied to a 13mL ATS 4B column as outlined in section 2.5.4. 
The column was eluted isocratically with lOmM DTT (—). Fractions were assayed for PAP-I
activity (•— •) as outlined in section 2.2.3, for protein ( ............... ) as outlined in section 2.4.2.1
and for 2-thiopyridone (o— o) as outlined in section 3.3.4. Fractions 19-24 were combined to form 
the post ATS 4B affinity chromatography pool (17mL).
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Purification stage Total Protein 
(mg)
Total Activity 
(units*)
Specific Activity 
(units/mg)
Purification Factor Recover;
(% )
Crude Homogenate 1713.6 260.0 0.15 1.00 100
Crude Cytosol (S2) 484.5 232.0 0.48 3.16 89.2
DEAE Sepharose 180.8 202.2 1.12 7.37 77.8
Sephadex G 100 10.4 110.3 10.61 69.94 42.4
ATS 4B 1.0 37.4 37.44 246.90 14.4
Table 3.3.1 Purification ofPyroglutamyl Aminopeptidase from  Bovine Brain C ytosol. *1 unit of enzyme activity is 
defined as that amount of enzyme which releases 1 nanomole of MCA per minute at 37°C
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3.4 Polyacrylamide Gel Electrophorseis
Polyacrylamide gel electrophoresis was carried out on samples from each step of the purification 
scheme. A photograph of the gel obtained following electrophoresis and silver staining (as outlined in 
section 2.6.3) is shown in figure 3.4.1. One distinct band was visualised in the lane containing post 
Activated Thiol Sepharose PAP-I. This band corresponded to a molecular weight of approximately 
24,680 Da.
116.000 Da
97.000 Da
66.000 Da 
48,500 Da
29,000 Da 
PAP-I
Fig 3.4.1 SDS PAGE Silver Stained Gel. A 16cm x 16cm x 1mm, 10% resolving gel, overlayed 
with a 3.5% stacking gel, was electrophoresed as outlined in section 2 .6 .2 . Samples which were 
prepared as outlined in section 2 .6 .1, were loaded in the following order:
Lane 1. Molecular weight markers 
Lane 2. Post affinity chromatography 
Lane 3. Post gel filtration 
Lane 4. Post ion exchange 
Lane 5. Crude cytosol (S2)
Lane 6 . Molecular weight markers
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3.5 Development of the pGlu-MCA Based Assay
The linearity of the pGlu-MCA based assay with respect to time was investigated as outlined in 
section 2.7.1. The release of MCA following incubation of pGlu-MCA with crude cytosol (S2) and 
post ion-exchange PAP-I for varying lengths of time is shown in figures 3.5.1 and 3.5.2 respectively. 
In both cases, the release of MCA with respect to time is linear over 1 hour.
The effect of BSA  on a purified preparation of cytosolic PAP was investigated. The release of MCA 
following incubation of pGlu-MCA with purified PAP-I in the presence of various concentrations of 
protease-fiee BSA  can be seen in figure 3.5.3. A minimum protein concentration of 1 to 2 mg/mL 
BSA  in the 100(j,L of purified preparation is required for optimum pGlu-MCA hydrolysis.
The linearity of the pGlu-MCA based assay with respect to time was investigated as outlined in 
sections 2.7.1 and 2.7.3. The release of MCA, in the presence and absence of BSA, following 
incubation of pGlu-MCA with post gel filtration and post affinity chromatography PAP-I is shown 
in figures 3.5.4 and 3.5.5 respectively. In both cases the release of MCA with respect to time is not 
linear in the absence of BSA. The presence of 2mg/mL BSA  in the 100|iL of PAP-I is required to 
keep the release of MCA linear with respect to time over the hour.
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Figure 3.5.1 Linearity of PAP-I Activity from the Supernatant with Respect to Time.
Supernatant (S2) was assayed over a range of times at 37°C as outlined in section 2.7.1. Liberated 
MCA was determined as outlined in sections 2.2.1 and 2.3. Error bars represent the SD of triplicate 
readings.
Time (minutes)
Figure 3.5.2 Linearity of PAP-I Activity from the Post Ion Exchange Pool with Respect to 
Time. Post D EAE ion exchange pool was assayed over a range of times at 37°C as outlined in 
section 2.7.1, Liberated MCA was determined as outlined in section 2.2,1. Error bars represent the 
SD of triplicate readings.
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Figure 3.5.3 The Effect of BSA  on a Purified Preparation of PAP-I. Purified PAP-I (post 
affinity chromatography) was combined with various concentrations of BSA  as outlined in section
2.7.2. Liberated M CA was determined as outlined in section 2.2.1. Error bars represent the SD of 
triplicate readings.
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Figure 3.5.4 Linearity of PAP-I Activity from the Post Gel Filtration Pool with Respect to 
Time. Post G100 gel filtration PAP-I was assayed over a range of times at 37°C in the presence 
(•— •) and absence (o— o) of 2mg/mL BSA  as outlined in sections 2.7.1 and 2.7.3. Liberated MCA 
was determined as outlined in section 2.2.1. Error bars represent the SD of triplicate readings.
Time (minutes)
Figure 3.5.5 Linearity of PAP-I Activity from the Post Affinity Chromatography Pool with 
Respect to Time. Post ATS 4B affinity chromatography PAP-I was assayed over a range of times 
at 37°C in the presence (•— •) and absence (o— o) of 2mg/mL BSA  as outlined in sections 2.7.1 and 
2.7.3. Liberated MCA was determined as outlined in section 2.2.1. Error bars represent the SD of 
triplicate readings
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3.6 Active Site Studies
3.6.1 The Effect o f M odifying Reagents on PAP-I Activity
The cffect of a range of modifying reagents on PAP-I activity was carried out as outlined in section
2.8.1. The effect of these reagents on PAP-I activity is summarised in tabic 3.6.1. Significant 
inhibition was observed using 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide,
dicthylpyrocarbonate, rose bengal, iodoacetamide, iodoacetic acid and N-Ethylmalemimide
3.6.2 Protection o f the Active Site by the Addition o f pGlu-His-Pro-NH2 (TRH)
The effect of protecting the active site with the competitive inhibitor TRH was carried out as 
outlined in section 2.8.3. The effect of this protection can be seen in table 3.6.2. It is evident, when 
TRH was present during the incubations, significant protection was afforded to the enzyme from 
inactivation by EDC, DEPC, rose bengal, iodoacetamide, IAA and NEM.
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Reagent Final Cone, 
(mM)
Activity as a %  of 
untreated samples ±SD
T etranitromethane 1 89.1+2.3 b
Phenylglyoxal 1 102.9 ±0.5 b
2,4,6 Trinitrobenzene
sulphonic acida 0.5 92.8 +1.7 b
Pyridoxal phosphate3 5 94.8 ± 1.0 b
Acetaldehyde“ 5 99.5 ± 4.4 b
1 -Ethyl-3 -(3 -Dimethylaminopropyl) 20 @ pH 5.0 98.7 ± 3.7 c
carbodiimide 20 @ pH 5.5 97.9 + 1.5 c
10 @ pH 6.0 94.3 + 1.0 b
10 @ pH 7.0 102.1 + 0.8 c
10 @ pH 8.0 5.0 +0.7 c
Diethylpyrocarbonate 2.5 36.8 + 0.3 c
10 1.7+ 0.5 c
Rose bengal 1 7.1 ± 0.2 c
SulDhvdrvl blocking reasents
Iodoacetamide 0.1 17.0 +0.8 c
Iodoacetic acid 0.1 42.6 ± 0.5 c
N-Ethylmalemimide 1 42.2 +0.8 c
N-Acetylimidazole 50 100.1 + 5.5 c
Table 3.6.1 The Effect o f  Various Protein-Modifying Reagents on PA P-I Activity. The effect of 
protein modifying reagents on PAP-I activity was determined as outlined in section 2.8.1. and 
residual activity determined as outlined in section 2 .2.1
a A ll assayed in the presence of 2mM sodium borohydride 
b Modifier removal prior to assay as outlined in section 2.8.2 
c Modifier not removed prior to assay
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Modifying reagent lm M TRH Activity as a %  of 
untreated samples ±SD
None - 100
1 -ethyl-3 -(3 -dimethylaminopropyl) - 5.0+ 0.7
carbodiimide (@  pH 8.0) + 18.9 ± 0.8
Diethylpyrocarbonate - 36.8 + 0.3
+ 78.5 ±7.8
Rose bengal - 7.1 ±0.2
+ 14.6 ± 1.3
Iodoacetamide - 17.0 ±0.8
+ 63.8 ± 1.6
Iodoacetic acid - 42.6 ±0.5
+ 82.4± 11.6
N-Ethylmalemimide - 42.2 ±0.8
+ 92.3 ±2.5
Table 3.6.2 Protective Effect o f  the Competitive Inhibitor TRH on the Inactivation o f  Purified 
PA P-I by M odifying Reagents. The effect of protein modifying reagents on PAP-I activity in the 
presence (+) and absence (-) of 3.75mM TRH was determined as outlined in section 2.8.3. Residual 
activity was determined as outlined in section 2 .2 .1.
3.6.3 Time course inhibition studies
The speed with which certain modifiers act on purified PAP-I was determined as outlined in section
2.8.4. The effect of EDC, IAA, NEM  and DEPC over time on PAP-I activity can be seen in figures
3.6.1, 3.6.2, 3.6.3 and 3.6.4 respectively. An immediate inhibition was observed for all four 
modifiers tested. In the case of IAA and NEM , TRH afforded significant protection immediately. In 
the case of DEPC the protective effect of TRH did not take effect until after 2 minutes, whereas with 
the EDC, TRH did not start protecting the en2yme until after approximately 10 minutes.
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Figure 3.6.1 Effect of ED C on PAP-I Activity over Time. Plot of residual PAP-I activity versus 
incubation time. Purified PAP-I was incubated over a range of times at 37°C with lOmM EDC in the 
presence (o— o) and absence (•— •) of 0.625mM TRH as outlined in section 2.8.4. Liberated MCA 
was determined as outlined in section 2.2.1. Error bars represent the SD of triplicate readings.
Incubation Time (minutes)
Figure 3.6.2 Effect of IA A  on PAP-I Activity over Time. Plot of residual PAP-I activity versus 
incubation time. Purified PAP-I was incubated over a range of times at 37°C with O.lmM IAA  in the 
presence (o— o) and absence (•— •) of 0.625mM TRH as outlined in section 2.8.4. Liberated MCA 
was determined as outlined in section 2.2.1. Error bars represent the SD of triplicate readings.
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Figure 3.6.3 Effect of N EM  on PAP-I Activity over Time. Plot of residual PAP-I activity versus 
incubation time. Purified PAP-I was incubated over a range of times at 37°C with ImM NEM  in the 
presence (o— o) and absence (•— •) of 0.625mM TRH as outlined in section 2.8.4. Liberated MCA 
was determined as outlined in section 2.2.1. Error bars represent the SD of triplicate readings.
Incubation Time (minutes)
Figure 3.6.4 Effect of D EPC  on PAP-I Activity over Time. Plot of residual PAP-I activity versus 
incubation time. Purified PAP-I was incubated over a range of times at 37°C with 2.5mM DEPC in 
the presence (o— o) and absence (•— •) of 0.625mM TRH as outlined in section 2.8.4. Liberated 
MCA was determined as outlined in section 2.2.1. Error bars represent the SD of triplicate readings.
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3.7 Stability Studies
3.7.1 Effect o f Potential Stabilisers on PAP-I Activity
The effect of various stabilisers on PAP-I activity was examined as outlined in section 2.9.1. Table
3.7.1 shows the effect of these stabilisers on PAP-I activity.
Potential Residual PAP-I activity as a percentage of the control ± SD
stabiliser
Concentrations (%  v/v, %  w/v or m M )a
5% 3.75% 125mM 10% 7.5% 250mM
Glycerol 93.3 + 5.7 88.3 ±0.4
Xylitol 94.8 ±2.6 76.6 ±2.3
Sucrose 87.4 ±3.8 87.0 ±6.7
PEG 131.5 ±4.4 131.0 ± 11.0
Glycine 107.3 ±6.0 124,4 ±8.1
Citrate 108.7 ± 1.1 100.5 ±3.4
Proline 98.5 ±4.9 81.8 ± 5.8
Control 100
BSA  (2mg/mL) 161,7 ± 4.0
Table 3.7.1 Effect o f  Various Potential Stabilisers on PA P-I Activity. The effect of potential 
stabilisers on PAP-I activity was determined as outlined in section 2.9.1. Residual activity was 
determined as outlined in section 2 .2 .1.
a See table 2.9.1 Note these are the concentrations in the lOOpL aliquots prior to assay
It is evident that, other than BSA  and PEG, none of the reagents showed any potential as stabilisers.
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3.7.2 Stability o f PA P-I During Assay
The linearity of the pGlu-MCA based assay with respect to time in the presence of PEG  was 
compared to that in the presence of BSA, as outlined in section 2.9.2. Figure 3.7.1 shows that PEG 
is not nearly as effective as BSA  in maintaining assay linearity. Even a combination of BSA  and 
PEG  is not as effective as BSA  alone.
3.7.3 Stability o f PAP-I During Storage
The stability of PAP-I during storage was assessed as outlined in section 2.9.3. Figure 3.7.2 shows 
that the presence of 1 or 2 mg/mL BSA  stabilises the enzyme, with over 80% of the original activity 
remaining after one month. Glycerol is not nearly as effective at stabilising PAP-I. 65% of the initial 
activity remains after one month at -80°C. When purified PAP-I is stored with no additions, only 
40% of the original activity remains after one day. This residual activity remains relatively constant 
throughout the month.
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Figure 3.7.1 The Linearity of Purified PAP-I Activity with Respect to Time. Post ATS 4B 
affinity chromatography PAP-I was assayed over a range of times at 37°C in the presence of BSA 
(o— o), PEG (A— A), BSA/PEG combination (♦— ♦) and without any additions (•— •), as outlined 
in section 2.9.2. Error bars represent the SD of triplicate readings.
Time (days)
Figure 3.7.2 Stability of Purified PAP-I. Plot of residual PAP-I activity versus time stored at 
-80°C. Post ATS 4B affinity chromatography was stored in the presence of 0.1% w/v BSA  (•— •), 
0.2% w/v BSA  (o— o), 15% v/v glycerol (♦— ♦) and without any additions (A—A) as outlined in 
section 2.9.3. Error bars represent the SD of triplicate readings.
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3.8 Initial Stabilisation of PAP-1 via Chemical Modification
3.8.1 Modification with EG-NHS and AA-NHS
Table 3.8.1 shows the effect of various concentrations of EG-NHS and AA-NHS on PAP-I activity.
Modifier concentration (mg/mL) Activity as a percentage of the control ± SD
EG-NHS AA-NHS
Control 100 100
1 108.6 ±3.0 N.D.
2 21.8 ±0.4 42.4 ±0.8
3 17.3 ±4.2 N.D.
4 18.7 ±4.4 24.9 ±0.8
Table 3.8.1 Effect o f  EG-NHS and AA-NHS on PA P-I Activity. The effect of NHS esters on 
PAP-I activity was determined as outlined in section 2.10.1. Activities are expressed as a percentage 
of the control (100%) in the absence of any modifier. N.D Not determined due to lack of material.
Concentrations of modifier higher than lmg/mL significantly inhibit the enzyme.
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3.8.2 Thermostability o f Native and M odified Enzyme
The thermostability of native and modified enzyme was determined as outlined in section 2.10.2. The 
result of this is shown in table 3.8.2. EG-NHS modified shows almost a twofold increase in 
thermostability over native (unmodified) PAP-I.
Modifier concentration (mg/mL) Activity as a percentage of the control
EG-NHS AA-NHS
Control 100 100
1 170.4 N.D.
2 105.5 81.4
3 22.7 N.D.
4 39.3 95.4
Table 3.8.2 The Thermostability o f  Native and Modified Enzyme. Native and modified PAP-I 
were heated at 55°C for 10 minutes. The activities are expressed as a percentage of the control 
(100%) in the absence of any modifier after heating at 55°C for 10 minutes. N.D. Not determined 
due to lack of material.
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Discussion
4.1 MCA Standard Curves: The Inner Filter Effect
Fluorimetric assays offer increased sensitivity over colourimetric assays (Blackmon et al., 1992; 
Lloyd, 1981; Rendell 1987). Due to the fact that all of the enzyme assays described in section 2.2 
are based on the release of MCA from specific substrates, a brief discussion on fluorescence 
spectrometry is warranted. Liberated MCA was quantified by reference to standard curves, prepared 
as outlined in section 2.3. Figures 3.1.1 to 3.1.4 are examples of standard curves obtained. The 
inclusion of biological samples such as crude homogenate or S2 of bovine brain in the standards 
resulted in a decrease in the slope of the curve, as illustrated in figures 3.1.1 and 3.1.2. This decrease 
is primarily due to two factors; the inner f i lte r  effect and quenching. It is not always clear from the 
literature, whether or not these phenomena have been taken into consideration by other investigators 
using fluorimetric enzyme assays.
The inner filter effect occurs whenever there is a compound present in the sample with an absorption 
band which overlaps either the excitation or emission band of the fluorescent analyte. Radiation at 
the excitation wavelength (370nm for MCA) may be absorbed before it can excite the fluorescent 
species. There may also be absorption of emitted radiation (440nm for MCA) before it leaves the 
cell. Other terms used to describe this effect include s e l f  absorption, prefilter  and pastfilter effects 
and the trivial effect. It becomes a problem when the absorption is high or when the concentration of 
the absorbing species, and therefore its absorbance, varies from sample to sample.
Quenching involves the removing of energy from a molecule in the excited state, by another 
molecule, usually as the result of a collision. This can be important in fluorescence spectrometry 
since the fluorescence of the analyte may be quenched by the molecules of other compounds present 
in the incubation mixture. Compounds containing heavy atoms (especially the heavier halogens) are 
effective quenching agents. Compounds containing unpaired electrons, such as molecular oxygen in 
aerated buffers, can also act as efficient quenching agents. However, it is apparent that the most 
common source of error and misinterpretation is due to the inner filter effect (Lloyd, 1981).
The purification of PAP-I from bovine brain is an example of how failure to consider the inner filter 
effect, could lead to misinterpretation of results. If  a standard curve incorporating S2 (see figure 
3 .1.2) had not been prepared, the total PAP-I activity in the supernatant would have been calculated 
to be 204 units, 12% lower than the actual value of 232 (sec table 3.3.1). Similarly, if a standard 
curve incorporating crudc homogenate had not been prepared (see figure 3.1.1) the total PAP-I 
activity in the starting sample would have been calculated to be 255 units, 2% lower than the actual
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value of 260 (table 3.3.1). As a result of this, an erroneous final yield of PAP-I would have been 
obtained. The quenching effect was not observed with any of the post column enzyme fractions.
Preparation of a standard curve, consisting of nine MCA concentrations, each in triplicate and 
incorporating enzyme, requires 2.7mL of enzyme sample. Although the presence of biological 
sample causes a decrease in slope, the standard curve remains linear over the MCA concentration 
range (figures 3.1.1 to 3.1.4). Therefore, in order to minimise the amount of sample required, mini­
standard curves were prepared which incorporated only two MCA concentrations (0[iM MCA and a 
top standard). This reduced the amount of sample required to 600pL per curve. In addition, it was 
found that 0.2% w/v BSA  in 50mM Tris/HCl buffer at pH 8.0 could be used instead of purified 
PAP-I containing 0.2% w/v BSA. This greatly reduced the amount of purified enzyme required for 
standard curve preparation during characterisation studies.
It should be noted that compounds other than biological samples were found to contribute to the 
inner filter/quenching effects. Some of the modifying reagents also contributed to the inner filter 
effect. This necessitated the preparation of quenched standard curves for each modifier as outlined 
above. For example, a decrease of 17.5% was observed in the slope when sample containing ImM 
rose bcngal was incorporated into the standard curve.
The final factor to be discussed in relation to fluorescence spectrophotometry is the geometry of the 
sample cell. The magnitude and characteristics of inner filter effects depends strongly on sample cell 
geometry (Lloyd, 1981). The cuvette based assays (1.5mL final volume) employ perpendicular 
geometry. In this case, the fluorescence emitted is collected along an axis at right angles to the 
excitation beam. Because of its freedom from the effects of scattered and transmitted excitation, this 
is the preferred arrangement (Lloyd, 1981). A ll quantitative assays were performed in this manner, 
using glass cuvettes. The microplate assays described in section 2.2.3, employ front surface 
geometry. In this arrangement, the fluorescence is collected and measured through the illuminated 
surface. Front surface geometry is particularly prone to inner filter effects and a high level of 
scattered light is diverted to the detector. As a result of these factors, coupled with the loss in 
sensitivity, due to the optical fibres contained in the microplate reader accessory, microplatc enzyme 
assays were used only for non-quantitative determinations.
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4.2 Purification of Cytosolic Pyroglutamyl Aminopeptidase from 
Bovine Brain.
The purification procedure used was a modification of that used by Cummins and O'Connor (1996). 
The main aim of the modification was to increase the yield of purified PAP-I. Yields from the 
original purification protocol were less than 7%. The entire purification procedure was carried out at 
4°C and the pH was maintained at 8.0 in order to minimise the loss of activity. An adsorption 
process was used as the first step due to its high capacity while gel-filtration, which has a much 
lower capacity, was used as an intermediate step. The sequence in which the chromatographic steps 
were arranged also served to minimise the length of time spent purifying the enzyme. The complete 
purification required approximately 30 hours.
Following the tissue preparation and centrifugation procedure outlined in section 2.5.1, 89% of the 
PAP-I activity was observed in the soluble fraction. This was an improvement on the original 
procedure, which had a yield of 80%. The main difference was the use of distilled water instead of 
buffer, in the resuspension of the first pellet. Researchers had suggested the use of an osmotic shock 
technique, using distilled water, in order to lyse entrapped vesicles formed during the homogenisation 
procedure, which may, and indeed does, harbour occluded enzyme activity (Van Amsterdam el al., 
1983). The use of a further osmotic shock step may yield more of the occluded activity but it will 
result in further dilution of the sample. It should also be noted that Mudge and Fellows (1973) have 
completely localised a pGlu-Ala hydrolysing activity from bovine pituitary homogenates to the 
soluble fraction following an ultracentrifugation procedure (100,000g).
Anion exchange chromatography using D EAE Sepharose Fast Flow proved an ideal first step in the 
purification of PAP-I from bovine brain. As can be seen from figure 3.3.1, most of the 
contaminating protein runs through the column under the conditions used. Application of a salt 
gradient results in elution of PAP-I. An excellent active recovery of 87% was achieved using this 
technique.
Gel filtration of post anion-exchange PAP activity on a Sephadex G100 column enabled excellent 
separation of PAP-I from other cytosolic components (figure 3.3.2). The main reason for the 
apparently low overall yield obtained using the original procedure was that only 18% active recovery 
was obtained using Sephacryl S200 H R gel filtration. Initial attempts to improve this yield centred 
around finding a column more suitable for the molecular weight of PAP-I and also finding a potential 
stabilising agent for the enzyme. It was decided that Sephadex G100 gel filtration would be more
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appropriate for the relatively low (24,000 daltons) molecular weight of PAP-I. Initial yields from this 
column appeared to be approximately the same as those from the Sephacryl S200 HR gel filtration 
column.
The reversible inhibitor and stabiliser, 2-pyrrolidone, has been previously used by researchers to 
stabilise PAP-I (Armentrout and Doolittle, 1969; Szewczuk and Kwiatkowska, 1970; Mudge and 
Fellows, 1973). Addition of 2-pyrrolidone into the sample prior to application to the gel filtration 
column, its inclusion in the running buffer and its subsequent removal by dialysis proved 
unsuccessful in stabilising PAP-I. Glycerol and BSA  are both widely used as enzyme stabilisers (see 
section 1.3.1.1.2 and 1.3.1.1.3). Glycerol and BSA  were added to the fraction collection tubes (in 
two different purification runs) prior to the gel filtration run in an attempt to find out if they would 
stabilise the enzyme as it comes of the column. The glycerol did not stabilise the PAP-I while the 
BSA  resulted in much higher yields (almost 55%).
Further investigation of this result lead to the discovery that during the assay of PAP-I from the 
G100 column, pGlu-MCA hydrolysis does not proceed in a linear fashion with respect to time (see 
figure 3.5.4). When BSA  was incorporated into the assay, the hydrolysis of the substrate proceeds in 
a linear fashion (for further discussion of this topic, see section 4.4), Development of the assay 
allows for a more accurate estimate of recovery from the G 100 gel filtration column (approximately 
55%).
Affinity chromatography of post gel filtration PAP-I activity exploited the sulphydryl nature of this 
enzyme and subsequently proved to be an efficient 'clean-up' step. Using an Activated Thiol 
Sepharose 4B column, PAP-I activity could be specifically bound to the column through the 
formation of disulphide linkages between the matrix functional groups and intact thiol groups located 
within the active site of the enzyme. The recovery of cytosolic PAP from this column was low (34% 
of total applied activity) but the excellent resolution of PAP-I from contaminating proteins (see 
figure 3.3.4) and a 10-fold reduction in protein justified its inclusion in the overall purification 
procedure. The low recovery is partly due to the fact that some of PAP-I does not bind to the 
column. Looking at figure 3.3.4, unbound activity appears minimal but the peak is masked 
somewhat by the 2-thiopyridone capping group coming off the column which quenches fluorescence 
during the microplate assay. The reason why all of the PAP-I does not bind may be explained as 
follows. The reducing agent, DTT, must be removed in a short time period. The enzyme thiol groups 
must be reduced, with all the disulphide groups converted to thiols. The reducing agent must be 
removed quickly in order to mimimise reversion of thiol groups to disulphide groups prior to
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chromatography. This may have occurred with some of the PAP-I molecules, but a balance must be 
struck in the dialysis time, between removal of most of the DTT and reversion of the thiol groups. 
The exact mechanism of affinity chromatography using Activated Thiol Sepharose 4B is briefly 
illustrated in Fig 4.3.3. For a more in depth review of this technique, see Brocklehurst et al. (1974).
An overall purification factor of247-fold with a 14.4% recovery was obtained for the purification of 
the enzyme from bovine brain (see table 3.3.1). This represents a significant improvement on the 
original purification procedure, which achieved a 91-fold purification factor and a 6.7% recovery 
(Cummins and O'Connor, 1996).
Activated Thiol Sepharose
(a) Thiol Enzyme
E-SH
h
o __ O
O ---  o --- E +
H ‘
Covalently bound enzyme 2-Thiopyridone
(b) l^ g   s --- E + R SH   ► |"— SH + E
+ R  S  S  R
RSH  = DTT, 2-Mercaptoethanol, Cysteine 
= Glutathione Spacer Arm
Figure 4.3.3, Protein purification strategy using Activated Thiol Sepharose (ATS), (a) Protein in 
reduced form  is applied to ATS resin that is capped with 2-Thiopyridone linked to Sepharose via a 
glutathione spacer arm. The protein binds covalently via a disulphide bond to the resin, replacing 
the capping group (2-Thiopyridone). (b). Application o f  reducing agent (RSH) such as DTT, 
reduces the disulphide bond, eluting the bound protein from the resin.
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4.3 Assessment of the Effectiveness of the PAP-I Purification 
Procedure using Polyacrylamide Gel Electrophoresis
The photographic evidence presented in figure 3.4.1 demonstrates that the gel filtration in particular 
effectively separates soluble PAP activity from the bulk of the proteins. This fact is corroborated by 
the 10-fold increase in specific activity obtained (see table 3.3.1). The inclusion of the affinity 
chromatography step is further justified by comparing lanes 2 and 3 in figure 3.4.1. ATS 4B affinity 
chromatography clearly removes several of the bands faintly visible in lane 3.
The silver stained band corresponding to purified PAP-I activity is clearly displayed in lane 2 of 
figure 3.4.1. Some additional bands are also faintly visible in this lane. As to whether these bands 
are contaminating protein or artefactual bands remains unclear. Bauer (1994) has suggested that 
aretfactual bands can arise during silver staining when 2-mercaptoethanol is used in the sample 
buffer (as in this case). It can be concluded that the enzyme has been purified to near homogeneity 
using this purification scheme. From the gel, the purified PAP-I can be seen to migrate slightly 
further than the carbonic anhydrase marker molecular (29,000 daltons) to a position representing a 
relative molecular mass of approximately 24,680. It should be noted that several workers have 
previously reported that soluble PAP activity of similar molecular mass. Mantle et al. (1990, 1991) 
have reported a native molecular mass of 22,000 daltons for soluble PAP activity isolated from 
human kidney and skeletal muscle. It also compares favourable with the molecular mass of 24,000, 
obtained from the same source by other workers in our laboratory (Cummins and O’Connor, 1996).
4.4 Development of the pGlu-MCA based assay
Oncc PAP-I was purified it was necessary to rc-cvaluate the assay procedure and determine the 
optimal conditions for PAP-I activity and assay linearity. For an enzyme assay to be reproducible 
and quantitative, substrate hydrolysis must be linear with respect to time and enzyme concentration. 
As mentioned in section 4.2, the PAP-I assay from post gel filtration samples was non-linear (see fig 
3.5.4). Therefore, it was necessary to perform assay development studies on post gel-filtration PAP-I 
as well as on purified PAP-I. When the assay for both was found to be optimal, all subsequent 
assays were performed as outlined in section 2.2.2. A ll figures presented in table 3.3.1 were obtained 
using the optimised assays.
The fluorogenic substrate pGlu-MCA was first used by Fujiwara and Tsuru (1978), who noted that 
the release of MCA could be followed with high sensitivity. The assay used throughout this project is
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a modification of the method used by Cummins and O’Connor (1996). The concentration of DTT in 
present in the substrate solution was increased from 2mM to lOmM in order to ensure full 
expression of PAP-I activity. It has been found that 6 to 8mM DTT is required for full expression of 
enzyme activity (unpublished results from our laboratory). EDTA was included in the assay mixture 
to chelate any metal ions, which can cause oxidation of thiol groups (see section 1.3.1.1.3).
The progress curves of most enzyme reactions are of the form shown in figure 4.4,
Figure 4.4 Linearity o f  Product Formation with Respect to Time
The time course is linear to begin with but the rate of product formation decreases with time. 
Various factors may contribute to this decrease and primary among these, in the case of PAP-I, is 
thought to be the enzyme's instability during assay. This is highlighted in the progress curves of 
PAP-I activity against pGlu-MCA shown in figures 3.5.1, 3.5.2, 3.5.4 and 3.5.5. These graphs 
illustrate that when supernatant (S2) or post ion exchange pool is used as the enzyme source, the 
reaction proceeds in a linear fashion over the one hour time period. When post gel filtration or post­
affinity chromatography samples are used, the reaction proceeds in a non-linear fashion, with the 
reaction rate departing from linearity in less than ten minutes. The inclusion of BSA  in the assay 
mixture restores linearity.
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As mentioned in section 1.3.1.1.3, BSA  is often included in reaction mixtures to stabilise dilute 
enzyme mixtures. Post gel filtration PAP-I is very dilute with a protein concentration of 19(ig/mL in 
a volume of 46mL. The binding of an enzyme to resins coupled with hydrophobic groups, like phenyl 
sepharose is indicative of hydrophobic residues on the enzyme surface (Schein, 1990). Indeed PAP-1 
does bind to phenyl sepharose when applied in 1M ammonium sulphate (results not shown). The 
hydrophobic interactions PAP-I makes with the highly hydrophobic molecule, BSA , will, as outlined 
in section 1.3.1.1.3, play a significant part in the stabilisation of PAP-I. As can be seen from figure
3.5.3, approximately l-2mg/mL BSA  is required for optimal stabilisation, and therefore activity, 
during assay.
4.5 Active Site Studies
To date, mammalian PAP-I has not been sequenced. Therefore, some knowledge of its active site 
would be useful, for example, in the synthesis of PAP-I inhibitors. A range of modifying reagents 
were used, as outlined in section 2 .8, in order to identify the amino acids at the active site of the 
enzyme. These results are presented in table 3.6.1.
Diethylpyrocarbonatc inhibited PAP-I at the two concentrations tested (2.5mM and lOmM). DEPC 
is a specific modifier of histidine residues (Dickenson and Dickenson, 1975). This suggests that a 
histidine residue is essential for activity. TRH is known to be a competitive inhibitor of PAP-I 
(Cummins and O'Connor, 1996). The presence of TRH offered significant protection against 
inactivation of the enzyme by DEPC (see table 3.6.2), a finding suggesting the essential nature of 
histidine in events at the active site. However, as can be seen from figure 3.6.4, this protective effect 
did not occur immediately, but did so after approximately 2 minutes. The effect lasts throughout the 
fifteen minute experiment, with the 'degree' of protection even increasing slightly. The fact that a His 
residue may be essential in catalysis is further substantiated by the fact that the enzyme is inhibited 
by rose bengal, which is reported to catalyse photooxidation of histidine residues (Cohen, 1970). 
Again, significant protection is afforded to the enzyme by the presence of TRH. It is worth 
mentioning at this point that His residues are known to have proton donor or acceptor function in 
many peptidase active sites.
N-Ethylmalcmimide, iodoacetic acid and iodoacetamide all significantly inhibited PAP-I (see table
3.6.1). Therefore, a cysteine residue is required for activity. This correlates with the previously 
known fact that PAP-I is a member of the cysteine protease family (Browne and O'Cuinn, 1983a; 
Cummins and O'Connor, 1996). When TRH was included in the assay with these modifiers,
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significant protection was afforded to the enzyme, indicative of the fact that cysteine plays an 
essential role in catalysis at the active site. As with the DEPC, TRH does not exert its affect in the 
presence of IA A  until approximately 2 minutes (see figure 3.6.2). When NEM  is used, the 
protective effect is almost instantaneous and the 'degree' of protection actually increases slightly 
throughout the course of the experiment. Cysteine also forms part of the catalytic site of PAP-I from 
some bacterial sources (Awade et ah, 1992b; Gonzales and Robert-Boudouy, 1994).
PAP-I is also significantly inhibited by l-ethyl-3-(3-dimethylaminopropyl)-carbodiimide. 
Carbodiimides are bivalent coupling reagents with the general formula R-N=C=R'. These water- 
soluble reagents have been used for the modification of carboxyl groups in proteins (Carraway and 
Koshland, 1972) to produce O-acylisoureas which in turn react with nucleophiles such as amino 
groups (Ji, 1983). Acidic conditions have been used in order to minimise cross-linking of carboxyls 
with lysine (a nucleophile) residues (Carraway and Koshland, 1972). Here, conditions of neutral to 
alkaine pH were required for inactivation. TRH affords the enzyme significant protection (see figure
3.6.1); therefore, aspartic acid and/or glutamic acid, in all probability, are essential for enzyme 
activity or substrate binding. Because of the pH required for inactivation, the possibility that lysine 
may be at the active site cannot be discounted.
2,4,6 Trinitrobenzene sulphonic acid, pyridoxal phosphate and acetaldehyde all fail to inhibit PAP-I, 
both in the presence and absence of sodium borohydride. A ll these compounds are specific for lysine 
residues. This, therefore, eliminates the possibility' that lysine forms part of the active site, as was 
suggested above.
Failure of N-acetylimidazole to inhibit PAP-I indicates that a tryosine residue is not essential for 
activity. N-acetylimidazole has been used primarily for the acetylation of tyrosyl residues (Riordan 
and Vallee, 1972a). This is further confirmed by the tetranitromethane result. As mentioned in 
section 1.3.2, TNM is involved in the nitration of tyrosine residues. Therefore, tyrosine is not 
required for enzyme activity. Arginine does not form part of the active site either because 
phenylglyoxal has no effect on the enzyme (Takahashi, 1977).
Therefore, along with Cys and His residues, Asp and/or Glu are necessary for enzymatic activity and 
they are all probably located at the active site. Interestingly, a similar study with PAP-I from 
Pseudomonas fluorescens camc to a similar conclusion, that Cys and His residues are essential for 
enzyme activity and that Asp, Glu, Asn and/or Gin complete the catalytic triad or tetrad (Gonzales 
and Robert-Baudouy, 1994). A more recent study by the same researchers on PAP from the same
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source came to the conclusion that Cys and His constitute the nucleophilic and imidazole residues of 
the active site, while Asp or Glu might constitute the third part of the active site (Le Saux et al., 
1996). This may also be true of PAP-I from a mammalian source. Tyr, Lys and Arg are not involved 
in the expression of catalytic activity of PAP-I from a mammalian source. Serine is also not involved 
in the expression of activity due to its lack of inhibition by phenylmethylsulphonylfluoride (Cummins 
and O'Connor, 1996).
4.6 Stability Studies
PAP-I is known to be an unstable enzyme (sections 1.2.1.1 and 4.4). BSA  has been found to stabilise 
the enzyme (section 4.4). However, an alternative to BSA  was sought. As mentioned in section 1.3.1, 
numerous low molecular weight substances are known to stabilise enzymes. A range of these were 
prepared as outlined in table 2.9.1. The reason for the preparation of these reagents can be explained 
as follows. Chemical modification of PAP-1 was to be attempted at a later date. Storage of PAP-I in 
BSA  would almost certainly interfere with these modifications, by 'mopping up' all, or most, of the 
modifier before it has a chance to act on PAP-I.
As can be seen from table 3.7.1, none of the additives tested were as effective as BSA  at increasing 
PAP-I activity. The only one which showed any promise was PEG. It was decided to test the 
effectiveness of PEG  in stabilising PAP-I during assay. From figure 3.7.1, it can be seen that, while 
PEG  increases the activity of PAP-I, it is not effective in maintaining assay linearity. Even a 
combination of BSA  and PEG  was not as effective as BSA  alone. Once these initial stability studies 
proved unsuccessful, it was concluded that it is a protein to protein interaction (most likely the 
hydrophobic interactions mentioned in section 4.4) that stabilises PAP-I. The only alternative was to 
attempt some initial chemical modifications with PAP-I stored in a lower concentration of BSA. It 
was already established that lmg/mL BSA was as effective as 2mg/mL BSA  in attaining optimum 
activity (figure 3.5.3). From figure 3.7.2, it can also be concluded that PAP-I is as stable, if not 
more so, in lmg/mL BSA as it is in 2mg/mL BSA  when stored at -80°C. Glycerol has been used 
regularly in the storage of enzymes; as can be seen from figure 3.7.2, it is not nearly as effective as 
BSA  in maintaining PAP-I activity during storage. OTagain, 1997 stated that while , it may seem 
foolish to add an exogenous, contaminating protein, such as BSA  deliberately to a pure protein 
preparation, occasionally this may be the price to be paid to avoid instability and inactivation. 
Therefore, purified PAP-I stored in lmg/mL BSA  was used for chemical modification studies.
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4.7 Stabilisation of PAP-I via Chemical Modification
PAP-I stabilisation was attempted using the N-hydroxysuccinimide esters, due to their mild chemical 
reaction conditions, their rapid rate of reaction and their specific targeting of amino groups, which 
have been found to be non-essential for catalytic activity (section 4.5). Despite this, concentrations 
of EG-NHS and AA-NHS higher than lmg/mL proved detrimental to PAP-I activity (table 3.8.1). 
Nevertheless, the thermostability of both native (unmodified) and modified PAP-I was assessed by 
heating both for 10 minutes at 55°C. Table 3.8.2 shows that the EG-NHS modified enzyme shows 
almost a twofold increase in thermostability over unmodified enzyme. AA-NHS modified enzyme at 
the concentrations used did not show any increase in thermostability. The possibility of increased 
thermostability with AA-NHS modified enzyme, at a concentration of lmg/mL, cannot be 
discounted. Crosslinking with agents such as NHS esters introduces 'braces' to the enzymes primary 
structure and this prevents the unfolding of the tertiary structure. Cross4inking was almost certainly 
successful in the case of EG-NHS. The cross-link(s) introduced probably prevented the enzyme 
structure from unfolding upon exposure to heat. Further work could focus on examining the 
resistance of this 'stabilised' enzyme to, for example, organic solvents or dénaturants. Careful choice 
of other cross-linkers, like the amino-specific bisimidates, could also lead to stabilisation. In 
conclusion, preliminary modification studies do show some promise although substantial work needs 
to be done in order to test the limits of this 'stabilised' enzyme.
4.8 Summary
Pyroglutamyl aminopeptidasc was purified from the cytosolic fraction of bovine whole brain by 
chromatography with D EAE sepharose, G100 gel filtration and ATS 4B affinity chromatography. 
This resulted in a 247-fold purification and a 14.4% recovery of enzyme activity.
Prior to further work, the PAP-I fluorimetric activity assay was optimised. This assay was found to 
be linear over an assay period of one hour, using IOO|xM pGlu-MCA prepared in 0.75% v/v DMSO. 
Because PAP-I is a cysteine protease, DTT was included in the assay at a concentration of lOmM. 
EDTA was also incorporated to chelate any inhibitory metal ions. The partially purified and purified 
enzyme was found to be unstable during assay. The inclusion of 1 or 2 mg/mL BSA  served to 
stabilise the enzyme, during assay and also during storage. Other potential stabilisers tested were not 
as effective as BSA  at increasing or maintaining PAP-1 activity (see table 3.7.1). The relative 
molecular mass of PAP-I, determined by SDS PAGE, was found to be 24,680 Da.
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PAP-I was confirmed to be a cysteine protease based on its sensitivity to IAA, NEM  and 
iodoacetamide. The enzyme was also inhibited by DEPC and EDC, suggesting that His and Glu 
and/or Asp are also involved in binding and/or catalytic activity at the active site. These results were 
confirmed by the protective effect of the competitive inhibitor TRH on inactivation of PAP-I by these 
modifying reagents. Cys and His may constitute the nucleophilic and imidazole residues of the active 
site, while Asp or Glu might constitute the third part of the active site. Lys, Tyr, Arg, and Ser are 
not involved in expression of activity and, therefore, do not take part in events at the active site.
Initial stabilisation via chemical modification demonstrated that EG-NHS-modified PAP-I showed 
almost a two-fold increase in thermostability over the native, unmodified enzyme. At the 
concentrations tested, AA-NHS modified enzyme did not show any increase in thermostability.
70
Bibliography
Abraham, G. N. andPodell, D. N. (1981), Pyroglutamic Acid: Non-Metabolic Formation, Function 
in Proteins and Peptides, and Characteristics of the Enzymes Affecting its Removal, Molecular and 
Cellular Biochemistry, 38, 181-190.
Albert, Z. and Szewczuk, A. (1972), Pyrrolidonyl Peptidase in Some Avian and Rodent Tissues: 
Histochemical Localization and Biochemical Studies, Acta Histochemica, 44, 98-105.
Armentrout, R. W . and Doolittle, R. F. (1969), Pyrrolidonecarboxylyl Peptidase: Stabilization and 
Purification, Archives o f  Biochemistry and Biophysics, 132, 80-90.
Awade, A., Cleuziat, P., Gonzales, T. and Robert-Baudouy, J. (1994), Pyrrolidone Carboxyl 
Peptidase (Pep): An Enzyme that Removes Pyroglutamic Acid (pGlu) from pGlu-Peptides and 
pGlu-Proteins, Proteins: Structure, Function, and Genetics, 20, 34-51.
Awade, A., Gonzales, T., Cleuziat, P. and Robert-Baudouy, J. (1992a), One Step Purification and 
Characterization of the Pyrrolidone Carboxyl Peptidase of Streptococcous pyogenes Over- 
Expressed in Escherichia coli, FEBSLetters, 308(1), 70-74.
Awade, A., Cleuziat, P., Gonzales, T. and Robert-Baudouy, J. (1992b), Characterization of the Pep 
Gene Encoding the Pyrrolidone Carboxyl Peptidase of Bacillus subtilis, FEBS Letters, 305(1), 67-
Bauer, K. (1994), Purification and Characterization of the Thyrotropin-Releasing-Hormone- 
Degrading Ectoenzyme, European Journal o f  Biochemistry, 224, 387-396.
Bauer, K. (1988), Degradation and Biological Inactivation of Thyrotropin Releasing Hormone 
(TRH): Regulation of the Membrane-Bound TRH-Degrading Enzyme from Rat Anterior Pituitary 
by Estrogens and Thyroid Hormones, Biochimie, 70, 69-74.
Bauer, K. (1987), Adenohypophyseal Degradation of Thyrotropin-Releasing Hormone Regulated by 
Thyroid Hormones, Nature, 330, 375-377.
Bauer, K., Nowak, P. and Kleinkauf, H. (1981), Specificity of a Serum Peptidase Hydrolysing 
Thyroliberin at the Pyroglutamyl-Histidine Bond, European Journal o f  Biochemistry, 118, 173-
71
Bauer, K. and Kleinkauf, H. (1980), Catabolism of Thyroliberin by Rat Adenohypophyseal Tissue 
Extract, European Journal o f  Biochemistry, 106, 107-117.
Bauer, K. and Nowak, P. (1979), Characterization of a Thyroliberin-Degrading Serum Enzyme 
Catalyzing the Hydrolysis of Thyroliberin at the Pyroglutamyl-Histidine Bond, European Journal o f  
Biochemistry, 99, 239-246.
Bigelow, C.C.(1967), Journal o f  Theoretical Biology, 16, 187-211.
Blackmon, D.L., Watson, A.J.M . and Montrose, M.H. (1992), Assay of Apical Membrane Enzymes 
Based on Fluorogenic Substrates, Analytical Biochemistry, 200, 352-358.
Borden, M., Holm, J., Laeslie, J., Sweetman, L., Nyhan, W .H., Nadler, H., Lewis, D. and Scott, 
C.R. (1992), Hawkinsinuria in Two Families, American Journal o f  M edical Genetics, 44, 52-56.
Bradford, M. (1976), A Rapid and Sensitive Method for Quantitation of Microgram Quantities of 
Protein Utilising the Principle of Protein-dye Binding, Analytical Biochemistry, 72, 248-254.
Brocklehurst, K., Carlsson, J., Kierstan, M .P.J. and Crook, E.M . (1974), Covalent Chromatography 
by Thiol-disulphide Interchange, In Methods in Enzymology, Jacoby, W .B. and Wilchek, M. (cds.), 
Academic Press, New York, 34, 531-544.
Browne, P. and O’Cuinn, G. (1983), An Evaluation of the Role of a Pyroglutamyl Peptidase, a Post- 
Prolinc Cleaving Enzyme and a Post-Proline Dipeptidyl Amino Peptidase, Each Purified From the 
Soluble Fraction of Guinea-Pig Brain, in the Degradation of Thyroliberin In Vitro, European 
Journal o f  Biochemistry, 137, 75-87.
Browne, P., Phelan, J. and O’Cuinn, G. (1981), TRH Pyroglutamate Aminopeptidase Activity in 
two Different Subcellular Fractions of Guinea-Pig Brain, Irish Journal o f  Medical Sciences, 150, 
348-349.
Bundgaard, H. and Moss, J. (1989), Prodrugs of Peptides IV : Bioreversible Derivatization of the 
Pyroglutamyl Group by N-Acylation and N-Aminomethylation to Effect Protection Against 
Pyroglutamyl Aminopeptidase, Journal o f  Pharmaceutical Sciences, 78(2), 122-126.
72
Capecchi, J. T. and Loudon, G. M. (1985), Substrate Specificity of Pyroglutamyl aminopcptidase, 
Journal o f  Medicinal Chemistry, 28, 140-143.
Carraway, K .L. and Koshland, D.E. (1972) Carbodiimide Modification of Proteins. In Methods in 
Enzymology, Hirs, C.H.W. and Timasheff, S.N. (eds.), Academic Press, New York, 25B, 616-622.
Charli, J.L ., Cruz, C., Vargas, M.A. and Joseph-Bravo, P. (1988), The Narrow Specificity 
Pyroglutamate Aminopeptidase Degrading TRH in Rat Brain is an Ectoenzyme, Neurochemistry 
International, 13(2), 237-242.
Charli, J-L., Mendez, M., Vargas, M-A., Cisneros, M., Assai, M., Joseph-Bravo, P. and Wilk, S. 
(1989), Pyroglutamyl Peptidase II Inhibition Specifically Increases Recovery of TRH Released from 
Rat Brain Slices, Neuropeptides, 14, 191-196.
Cohen L.A. (1970), Chemical Modification as a Probe of Structure and Function in The Enzymes, 
Volume 1, 3rd edition, Boyer P ed. Academic Press Inc, New York, 148-211.
Cummins, P.M. and O'Connor, B. (1996), Bovine Brain Pyroglutamyl Aminopeptidase (type-1): 
Purification and Characterization of a Neuropeptide-inactivating Peptidase, International Journal o f  
Biochemistry and Cell Biology, 28(8),883-893.
Dealler, S.F., Campbell, L., Kerr, K.G., McGoldrick, J., Flannigan, K.A. and Hawkey, P.M. 
(1989), Reliable Five-minute Test Strip Method for Identification of Streptococcus pyrogenes, 
European Journal o f  Clinical Microbiology and Infectious Diseases, 8 , 308-310.
De Gandaris J.M ., Irazusta, J., Silio, M., Gil, J., Siatua, N. and Casis L. (1998), Soluble and 
Membrane-bound Pyroglutamyl-aminopeptidase I Activity in the Developing Cerebellum and Brain 
Cortex, Int. J.Dev.Biol, 42(1), 103-106.
Dickenson, C .J and Dickenson, F. M. (1975), Role of an Essential Histidyl Residue of Yeast Alcohol 
Dehydrogenase, Eur. J. Biochem., 52, 595-603.
Doolittle, R. F. (1972), Terminal Pyrrolidonecarboxylic Acid: Cleavage with Enzymes, In Methods 
in Enzymology, Hirs, C. H. W . and Timasheff, S. N. (eds.), Academic Press, New York, 25B, 231- 
244.
73
Doolittle, R. F. and Armentrout, R. W. (1968), Pyrrolidonyl Peptidase. An Enzyme for Selective 
Removal of Pyrrolidonecarboxylic Acid Residues from Polypeptides, Biochemistry, 7(2), 516-521.
Edman, P. (1950), Method for the Determination of the Amino Sequence in Peptides, Acta Chemica 
Scandinavica, 4, 283-293.
Fischer, W .H. and Speiss, J. (1987), Identification of a Mammalian Glutaminyl Cyclase Converting 
Glutaminyl into Pyroglutamyl Peptides, Proceedings o f  the National Academy o f  Sciences USA, 84, 
3628-3632.
Friedman, T. C. and W ilk, S. (1986), Delineation of a Particulate Thyrotropin-Releasing Hormone- 
Degrading Enzyme in Rat Brain by the use of Specific Inhibitors of Prolyl Endopeptidase and 
Pyroglutamyl Peptide Hydrolase, Journal o f  Neurochemistry, 46(4), 1231-1239.
Friedman, T. C., Kline, T. B. and W ilk, S. (1985), 5-Oxoprolinal: Transition-State Aldehyde 
Inhibitor of Pyroglutamyl-Peptide Hydrolase, Biochemistry, 24, 3907-3913.
Fujiwara, K., Matsumoto, E., Kitagawa, T. and Tsuru, D. (1982), N-Alpha-Carbenzoxy 
Pyroglutamyl Diazomethyl Ketone as Active-Site-Dirccted Inhibitor for Pyroglutamyl Peptidase, 
Biochimica et Biophysica Acta, 702, 149-154.
Fujiwara, K., Matsumoto, E., Kitagawa, T. and Tsuru, D. (1981a), Inactivation of Pyroglutamyl 
Aminopeptidase by vV-Alpha-Carbcnzoxy-L-Pyroglutamyl Chloromethyl Ketone, Journal o f  
Biochemistry, 90, 433-437.
Fujiwara, K , Kitagawa, T. and Tsuru, D. (1981b), Inactivation of Pyroglutamyl Aminopeptidase 
by L-Pyroglutamyl Chloromethyl Ketone, Biochimica et Biophysica Acta, 655, 10-16.
Fujiwara, K. and Tsuru, D. (1978), New Chromogenic and Fluorogenic Substrates for Pyrrolidonyl 
Peptidase, Journal o f  Biochemistry, 83, 1145-1149.
Gonzales, T. and Robert-Baudouy, J. (1994), Characterization of the pep Gene of Pseudomonas 
fluorescens and its Product, Pyrrolidone Carboxyl Peptidase (Pep), Journal o f  Bacteriology, 
176(9), 2569-2576.
74
Gonzales, T. and Awade, A. (1992), Purification and Characterization of Recombinant Pyrrolidone 
Carboxyl Peptidase of Bacillus subtilis, Journal o f  Chromatography, 584, 101-107.
Greaney, A., Phelan, J. and O’Cuinn, G. (1980), Localization of Thyroliberin Pyroglutamyl 
Peptidase on Synaptosomal-Membrane Preparations of Guinea-Pig Brain Tissue, Biochemical 
Society Transactions, 8(4), 423.
Griffiths, E. C., Kelly, J. A., White, N. and Jeffcoate, S. L. (1979), Hypothalamic Inactivation of 
Thyroliberin (Thyrotropin-Releasing Hormone), Biochemical Society Transactions, 7, 74-75.
Grioli, S., Lomeo, C., Quattopani, M.C., Spignoli, G. and Vilardita, C. (1990), Pyroglutamic Acid 
Improves the Age-associated Memory Impairment, Fundamental Clinical Pharmacology, 4, 169- 
173.
Hayes, D. J., Phelan, J. J. and O’Cuinn, G. (1979), The Metabolism of Thyrotropin-Releasing 
Hormone by Guinea-Pig Brain, Biochemical Society Transactions, 7, 59-62.
Helmerhorst, E. and Stokes, G.B. (1980), Microcentrifuge Desalting: A Rapid Quantitative Method 
for Desalting Small Amounts of Protein, Anal. Biochem, 104, 130-135.
Heukshoven, J. and Demick, R. (1985), Simplified Method for Silver Staining of Proteins in 
Polyacrylamide Gels and the Mechanism of Silver Staining, Electrophoresis, 6(3), 103-112.
Inoue, K , Miki, K , Tamura, K. and Sakazaki, R. (1996), Evaluation of L-pyrrolidonal Peptidase 
Paper Strip Test for Differentiation of Members of the Family Enterobacteriaceae, particularly
Salmonella spp., J. Clin. Microbiol., 34(7), 1811-2.
Izu, Y., Tanaka, T., Miyagi, M., Tanigawa, T., Tomono, J., Tsunasawa, S. and Kato, I (1998), 
Enzyme for Removing the Amino-terminal Protecting Groups from Peptides, Patent Number 
W09749819.
Ji T.H. (1983) Bifunctional Reagents, in Methods Enzymol. Hirs, C.H.W. and Timascheff, S.N., 
eds. Academic Press, New York. 91, 580-609.
75
Khande, K.M ., Fairwel, T., Chait, B.T. and Manjula, B .N. (1989), Influence of Ions on Cyclisation 
of the Amino-terminal Glutamine Residues of Tryptic Peptides of Streptococcal PepM49 Protein: 
Resolution of Cylcised Peptides by HPLC and Characterisation by Mass Spectrometry, 
International Journal o f  Peptide and Protein Resaerch, 34, 118-123.
Kwiatkowska, J. Torain, B. and Glenner, G. (1974), A Pyrrolidonecarboxylate Peptidase from the 
Particulate Fraction of Klebsiella cloacae: Purification of the Stable Enzyme and its use in 
Releasing the NH2 Terminus from Pyrrolidonccarboxylyl Peptides and Proteins, The Journal o f  
Biological Chemistry, 249(24), 7729-7736.
Kyte, J. and Doolittle, R.F. (1982), A Simple Method for Displaying the Hydropathic Character of a 
Protein, Journal o f  Molecular Biology, 157, 105-132.
Laemmli, U.K. (1970), Cleavage of Structural Proteins during Assembly of the Head of 
Bacteriophage T4, Nature (London), 227, 680-685.
Lauffart, B., McDermott, J. R., Biggins, J. A., Gibson, A. M. and Mantle, D. (1988), Purification 
and Characterization of Pyroglutamyl Aminopeptidase From Human Cerebral Cortex, Biochemical 
Society Transactions, 17(1), 207-208.
Le Saux, O., Gonzales, T. Robert-Baudouy, J. (1996), Mutational Analysis of the Active Site of 
Pseudomonas fluorescens Pyrrolidine Carboxyl Peptidase, J. Bacteriol, 178(11), 3308-3313.
Lloyd, J.B .F. (1981), Inner Filter Effects, Sample Cells and Their Geometry in Fluorescence 
Spectrometry, in Standards in Fluorescence Spectrometry, Miller, J.N . (ed.), Chapman and Hall, 
London, 27-43.
Lu, H.S., Clogston, C.L., Wypych, J., Fausset, P.R., Lauren, S., Mendiaz, E.A., Zsebo, K.M. and 
Langley, K .E. (1991), Amino Acid Sequence and Post Translational Modification of Stem Cell 
Factor Isolated from Buffalo Rat Liver Cell-conditioned Medium, Journal o f  Cell Biology, 266, 
8102-8107.
Mantle, D. (1992), Comparison of Soluble Aminopeptidases in Human Cerebral Cortex, Skeletal 
Muscle and Kidney Tissues, Clinica Chimica Acta, 207, 107-118.
76
Mantle, D., LaufFart, B. and Gibson, A. (1991), Purification and Characterization of Leucyl 
Aminopeptidase and Pyroglutamyl Aminopeptidase from Human Skeletal Muscle, Clinica Chimica 
Acta, 197, 35-46.
Mantle, D., Lauffart, B., McDermott, J. and Gibson, A. (1990), Characterization of 
Aminopeptidases in Human Kidney Soluble Fraction, Clinica Chimica Acta, 187, 105-114.
McDonald, J. K. and Barrett, A. J. (1986), Mammalian Proteases: A Glossary and Bibliography
Vol. 2. In Exopeptidases, Academic Press, London.
Means, G.E. and Feeney, R.E. (1990) Chemical Modification of Proteins: History and Applications. 
Bioconjugate. Chem. 1, 2-12.
Mendez, M., Cruz, C., Joseph-Bravo, P., W ilk, S. and Charli, J-L. (1990), Evaluation of the Role of 
Prolyl Endopeptidase and Pyroglutamyl Peptidase I  in the Metabolism of LH-RH and TRH in Brain,
Neuropeptides, 17(2), 55-62.
Messer, M. (1963), Enzymatic Cyclisation of L-Glutamine and L-Glutaminyl Peptides, Nature, 197, 
1299
Miyatakc, N., Kamo, M., Satake, K , Uchiyama, Y. and Tsugita, A. (1993), Removal of N- 
Terminal Formyl Groups and Deblocking of Pyrrolidone Carboxylic Acid of Proteins with 
Anhydrous hydrazine Vapor, European Journal o f  Biochemistry, 212, 785-789.
Moss, J. and Bundgaard, H. (1992), Prodrugs of Peptides: 19. Protection of the Pyroglutamyl 
Residue Against Pyroglutamyl Aminopeptidase by N-Acycloxymethylation and Other Means, Acta 
PharmaceuticaNordica, 4(4), 301-308.
Moss, J. and Bundgaard, H. (1989), Prodrugs of Peptides: 5. Protection of the Pyroglutamyl 
Residue Against Pyroglutamyl Aminopeptidase by Bioreversible Derivatization with Glyoxylic Acid 
Derivatives, International Journal o f Pharmaceutics, 52(3), 255-263.
Mozdzanowski, J., Bongers, J. and Anumula, K. (1998) High Yield Deblocking of Amino Termini 
of Recombinant Immunoglobulins with Pyroglutamate Aminopeptidase. Anal.Biochem, 260(2), 183- 
187.
77
Mozhaev, V.V., Siksnis, V.A., Melik-Nubarov, N.S., Galkantaite, N.Z., Denis, G .J, Butkus, B.P., 
Zaslavsky, B.Y ., Mcstechkina, N.M. and Martinek, K.(1988), Protein Stabilisation via 
Hydrophilization, Eur. J. Biochem, 173, 147-154.
Mozhaev, V.V. and Martinek, K. (1984), Structure-stability Relationships in Proteins: New
Approaches to Stabilising Enzymes, Enzyme Microb. Technol., 6, 50-59.
Mudge, A. W . and Fellows, R. E. (1973), Bovine Pituitary Pyrrolidonecarboxylyl Peptidase, 
Endocrinology, 93(6), 1428-1434.
O’Connor, B. and O’Cuinn, G. (1984), Localization of a Narrow-Specificity Thyroliberin- 
Hydrolysing Pyroglutamate Aminopeptidase in Synaptosomal Membranes of Guinea-Pig Brain, 
European Journal o f  Biochemistry, 144, 271-278.
Ö Fagäin, C. (1997), Stabilising Protein Function, Springer-Verlag Berlin Heidelberg.
Ö Fagäin, C. and Kennedy, R. (1991), Functionally Stabilised Proteins- a Review, Biotech. Adv., 9, 
351-409.
Ö Fagäin, C., Sheehan, H., O'Kennedy, R. and Kilty, C. (1988), Maintenance of Enzyme Structure. 
Possible Methods for Enhancing Stability, Process Biochemistry, 23, 166-171.
Orlowski, M. and Meister, A. (1971), Enzymology of Pyrrolidone Carboxylic Acid, In The Enzymes
: TV: Hydrolysis, Boyer, P.D. (ed.), Academic Press, New York and London, 123-151.
Orlwoski, M., Richman, P.G. and Meister, A. (1969), Isolation and Properties of y-Lglutamyl 
cyclotransferasc from Human Brain, Biochemistry, 8 , 1048-1055.
Panosian, K .J. and Edberg, S.C. (1989), Rapid Identification of Streptococcus bovis by using a 
Combination of Constitutive Enzyme Substrate Hydrolyses, Journal o f  Clinical Microbiology, 27, 
1719-1722.
Podell, D. N. and Abraham, G. N. (1978), A Technique for the Removal of Pyroglutamic Acid from 
the Amino Terminus of Proteins Using Calf Liver Pyroglutamate Amino Peptidase, Biochemical 
and Biophysical Research Communications, 81(1), 176-185.
78
Prieto, I., Mattinez, A., Martinez, JM ., Ramirez, M J., Vargas, F., Alba, F. and Ramirez, M (1998). 
Activities of Aminopeptidases in Rat Saline Model of Volume Hypertension. Horm. Me tab. Res. 
30(5), 246-248.
Rendell, D. (1987), Quantitative Fluorimetry, in Fluorescence and Phosphorescence (Analytical 
Biochemistry), Mowthorpe, D. (ed.), John W iley &  Sons, Chichester, 88-159.
Riordan, J.F. and Vallee, B.L. (1972a) Acetylation. In Methods Enzymol., Hirs, C.H.W. and 
Timasheff, S.N. eds, Academic Press, New York, 25B, 494-499.
Riordan, J.F. and Vallee, B.L. (1972b) Nitration with Tetranitromethane. In Methods Enzymol. 
Hirs, C.H.W. and Timasheff, S.N. eds, Academic Press, New York, 25B, 515-521
Salers, P., Ouafik, L., Giraud, P., Dutour, A., Maltese, J-Y. and Oliver, C. (1991), Evidence for 
Pyroglutamyl Peptidase I and Prolyl Endopeptidase Activities in the Rat Insulinoma Cell Line RINm 
5F: Lack of Relationship with TRH Metabolism, Molecular and Cellular Biochemistry, 106(1), 15- 
24.
Sanger, F., Thompson, E.O.P. and Kitai, R. (1955), The Amide Groups of Insulin, Biochemical 
Journal, 59, 509-518.
Schein C.H. (1990), Solubility as a Function of Protein Structure and Solvent Components, 
Biotechnology, 8 , 308-317.
Schock, D. (1977), TRH Degrading Enzymes in Brain, Anatomical Record, 187, 707-708.
Scopes, R.K. (1994) Protein Purification: Principles and Practice. 3rd ed. Berlin: Springer Verlag, 
317-324.
Shaw, PJ., Incc, PG., Falkous, G. and Mantle, D (1996). Cytoplasmic, Lysosomal and Matrix 
Protease Activities in Spinal Cord Tissues from Amylotrophic Lateral Sclerosis (A LS) and Control 
Patients. J.Neuro.Sci., 139 Suppl, 71-75.
Smith, P.K., Krohn, R .I, Hermansion, G.T., Mallia, A.K., Gartner, F.H., Provenzano, M.D., 
Fujimoto, E.K., Goeke, N.M, Olsen, B .J. and Klenk, D.C. (1985), Measurement of Protein using 
Bicinchoninic Acid, Analytical Biochemistry, 150, 76-85.
79
Spignoli, G., Magnani, M., Giovannini, M. and Pepeu, G. (1987), Effect of Pyroglutamic Acid 
Steroisomers on ECS and Scopolamine-Induced Memory Disruption and Brain Acetylcholine levels 
in rat, Pharmacological Research Communications, 19, 901-912.
Suen, C-S. and W ilk, S. (1989), Sodium Butyrate Induces Pyroglutamyl Peptidase I and Decreases 
Thyrotropin-Releasing Hormone Receptors in GH3 Cells, Endocrinology, 124(4), 1654-1660.
Szewczuk, A. and Kwiatkowska, J. (1970), Pyrrolidonyl Peptidase in Animal, Plant and Human 
Tissues: Occurrence and Some Properties of the Enzyme, European Journal Biochemistry, 15, 92-
Szewczuk, A. and Mulczyk, M. (1969), Pyrrolidonyl Peptidase in Bacteria: The Enzyme from 
Bacillus subtilis, European Journal o f  Biochemistry, 8, 63-67.
Taylor, W. L. and Dixon, J. E. (1978), Characterization of a Pyroglutamate Aminopeptidase from 
Rat Serum that Degrades Thyrotropin-Releasing Hormone, Journal o f  Biological Chemistry, 
253(19), 6934-6940.
Takahashi, K.(1977), Further Studies on Reactions of Phenylglyoxal and Related Reagents with 
Proteins, J. Biochem, 81, 403-414.
Torichilin, V.P., Maksimenko, A.Y., Smirnov, V .N , Berezin, I.V ., Klibanov, A.M. and Martinek, 
K. (1978). The Principles of Enzyme Stabilisation III. The Effect of the Length of Intramolecular 
Cross-Linkages on Thermostability of Enzymes. Biochimica et Biophysica Acta, 522, 277-283.
Tsuru, D., Nakamura, K., Yoshimoto, T. and Fujiwara, K. (1984), Pyroglutamyl Peptidase from 
Bacillus amyloliquefaciens: An Improved Purification Method and Some Properties of the Enzyme, 
Biochimica et Biophysica Acta, 791, 117-122.
Tsuru, D., Fujiwara, K. and Kado, K., (1978), Purification and Characterization of L- 
Pyrrolidonecarboxylate Peptidase from Bacillus amyloliquefaciens, Journal o f  Biochemistry, 84, 
467-476.
Uhlhaas, S. and Lange, H. (1988), Strial Deficiency of L-Pyroglutamic Acid in Huntington's 
Disease is Accompanied by Increased Plasma Levels, Brain Research, 457, 196-199.
80
Van Amsterdam, J.G.C., Van Buuren, K.J.H . and Soudijn, W. (1983), Purification and 
Characterisation of Enkephalin-degrading Enzymes form Calf-Brain Striatum, Biochemical and 
Biophysical Research Communications, 115, 632-641.
Van der Werf, P., Griffith, O.W. and Meister, A. (1975), 5-oxo-L-prolinase (L-pyroglutamate
hydrolase): Purification and Catalytic Properties, Journal o f  Biological Chemistry, 250, 6686-6692.
Wellstood, S.A. (1987), Rapid Cost-effective Identification of Group A streptococci and 
enterococci by Pyrrolidonyl-p-naphthylamide Hydrolysis, Journal o f  Clinical Microbiology, 25, 
1805-1806.
W ilk, S. (1986), Neuropeptide-specific peptidases: Does brain contain a specific TRH-degrading 
enzyme, Life Science, 39, 1487-1492.
W ilk, S., Friedman, T. C. and Kline, T. B. (1985), Pyroglutamyl Diazomethyl Ketone: Potent 
Inhibitor of Mammalian Pyroglutamyl Peptide Hydrolase, Biochemical and Biophysical Research 
Communications, 130(2), 662-668.
Winstead, J.A . and Wold, F. (1962), Studies on Rabbit Muscle Enolase: Chemical Evidence for two 
Polypeptide Chains in the Active Enzyme, Journal o f  Clinical Endocrinology and Metabohsm, 39, 
791-795.
Yoshimoto, T., Shimoda, T., Kitazono, A., Kabashima, T., Ito, K. and Tsuru, D. (1993), 
Pyroglutamyl peptidase gene expression from Bacillus amyloliquefaciens: Cloning, Sequencing, 
Expression and Crystallization of the Expressed enzyme, Journal o f  Biochemistry, 113, 67-73.
81
